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Abstract 
 
Necroptosis, a type of regulated necrotic cell death, involves cell membrane 
permeabilization and has been implicated in various acute and chronic pro-
inflammatory diseases, including ischemia-reperfusion injury and 
neurodegenerative diseases. By using in vitro reconstitution studies and a 
chemical inhibitor, the kinase activity of the serine/threonine kinase RIPK1 had 
been shown to regulate necroptotic signaling downstream of TNF and Toll-like 
receptors (TLRs). To investigate the contribution of RIPK1 kinase activity to 
inflammation and necroptosis in vivo, we generated kinase inactive RIPK1 knock-
in mice. Utilizing fibroblasts and macrophages from these mice, we demonstrate 
that RIPK1 kinase activity is required for necroptotic complex formation and death 
induction downstream of TNFR1 and TLRs 3 and 4. We show that RIPK1 kinase 
inactive mice are resistant to TNF-induced shock and exhibit impaired upregulation 
of TNF-induced cytokines and chemokines in vitro and in vivo. By using bone 
marrow reconstitution experiments, we demonstrate that RIPK1 kinase activity in 
a non-hematopoietic lineage drives TNF-induced lethality. We establish that 
RIPK1 kinase activity is required for TNF-induced increases in intestinal and 
vascular permeability and clotting, and implicate endothelial cell necroptosis as an 
underlying factor contributing to TNF/zVAD-induced shock. Thus, work in this 
thesis reveals that RIPK1 kinase inhibitors may have promise in treating shock and 
sepsis. 
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The role of cell death in inflammation and disease 
Cell death is an integral part of multicellular organism survival, playing 
important roles during development and maintaining tissue and organismal 
homeostasis by eliminating damaged or infected cells. However, deregulation or 
inhibition of cell death can lead to inflammation and disease. Thus, discovering the 
signaling pathways linking cell death and inflammation is crucial to understanding 
disease pathogenesis and potential therapeutic strategies. Over the last few 
hundred years, based on the study of cell morphology during various processes in 
organisms, an idea of the existence of regulated cell death and accidental cell 
death has emerged1,2.  
In 1972, Kerr and colleagues introduced ‘apoptosis’ to describe a type of 
morphologically distinct regulated cell death they had observed. Apoptotic 
morphology includes cell shrinkage, pyknosis (chromatin condensation), 
karyorrhexis (nuclear fragmentation), and apoptotic body formation3. Subsequent 
studies, first in C. elegans, defined the genetic program of apoptotic death4,5. 
Apoptosis in vertebrates was found to be mediated by a family of cysteine 
proteases termed caspases, since they cleave after aspartic acid residues6–8. 
Caspases are synthesized as zymogens, and upon initiator caspase cleavage and 
activation, they  activate executioner caspases like caspase-3 to cleave various 
cellular substrates and induce the morphological changes associated with 
apoptotic cell death9. Two apoptotic pathways have been discovered: intrinsic and 
extrinsic apoptosis. The intrinsic pathway can be activated by signals such as 
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growth factor depletion, toxins, hypoxia or free radicals, and involves intricate 
regulation by anti- and pro-apoptotic Bcl2 family members, mitochondrial outer 
membrane permeabilization, release of second mitochondria-derived activator of 
caspases (SMAC) and cytochrome c from the mitochondria, and activation of the 
executioner caspase-910.  
Meanwhile, the extrinsic pathway is induced by ligand binding to 
corresponding death receptors of the tumor necrosis factor (TNF) receptor gene 
superfamily (TNFRSF), such as Fas ligand binding to the Fas receptor or the 
cytokine TNF-α binding to its receptor, TNF receptor 1 (TNFR1)11. These death 
receptors were found to contain a roughly 80-amino acid long C-terminal “death 
domain” (DD)12,13 which allows for recruitment and interaction with cytoplasmic 
death-domain containing adaptor proteins such as TNF-receptor-associated death 
domain (TRADD)14, receptor interacting protein kinase 1 (RIPK1)15, and Fas-
associated death domain (FADD)16,17. Through its death effector domain (DED)18, 
FADD binds the initiator caspase-819,20, which upon activation mediates 
downstream executioner caspase cleavage and induction of apoptosis. 
Historically, apoptosis has been viewed as an immunologically silent, or 
tolerogenic type of cell death. Plasma membrane flipping and exposure of 
phosphatidylserine early during apoptosis allows for recognition and clearance of 
apoptotic cells and bodies by cells of the innate immune system such as resident 
tissue macrophages21,22. Thus, apoptotic cells do not release their intracellular 
contents and their phagocytosis by innate immune cells typically doesn’t produce 
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an inflammatory response23. While apoptosis occurring during development or 
normal cellular turnover certainly seems to be non-immunogenic, cell death due to 
infection or tissue injury with accompanying inflammation may be beneficial in 
alerting the immune system to repair the tissue or eliminate a pathogen. Indeed, 
excessive apoptosis in various mouse models, especially in epithelial barrier tissue 
such as the skin, can induce inflammation in vivo24–27, suggesting apoptosis can 
be inflammatory in certain contexts. 
While intense study was devoted to regulated apoptotic cell death, a 
necrotic morphology was thought to be unregulated and accidental. Necrosis can 
be caused by harsh physical or chemical stimuli, such as trauma, burns, or rapid 
changes in temperature or pH. Morphologically, necrosis involves cytoplasmic and 
organelle swelling, plasma membrane breakdown, and release of damage-
associated molecular patterns (DAMPs)2. Over the last 30 years, many studies 
have shown that necrosis can be regulated, and multiple sub-types of programmed 
necrotic death have been delineated. In 1988, Laster et al., showed that depending 
on the cell line, TNF could induce apoptotic or necrotic cell death28. In the late 
1990s Peter Vandenabeele’s group and others demonstrated that, primarily in 
caspase-8 deficient cells or upon caspase inhibition, death receptor signaling 
downstream of TNF or Fas induces caspase-independent necrotic cell death29–35. 
Importantly, Holler and colleagues found a requirement for the kinase activity of 
the death receptor signaling component RIPK1 in mediating Fas, TNF, or TNF-
related apoptosis-inducing ligand (TRAIL)-induced caspase-8-independent 
5 
 
 
 
necrotic cell death36. Chan et al. introduced the term “programmed necrosis” to 
refer to this RIPK1-dependent necrotic death and demonstrated in 2003 that TNF 
stimulation of vaccinia virus-infected Jurkat T cells induces programmed necrosis. 
Additionally, certain viral gene products can inhibit this death, suggesting a 
potential in vivo role for programmed necrosis in regulating viral infection37. Finally, 
in 2005 this regulated necrotic death was named “necroptosis”, and a small 
molecule inhibitor was identified that inhibits RIPK1 kinase activity38,39. Research 
over the last decade has shown that death receptor-induced necroptosis, a 
regulated form of necrosis, is mediated by RIPK124,39–41 and receptor interacting 
protein kinase 3 (RIPK3)41–44 kinase activity, leading to activation of the down-
stream pseudokinase mixed-lineage kinase like (MLKL)45–48. 
While necroptosis has been the most studied sub-type of regulated necrotic 
death, many other forms of programmed necrosis have been found, including 
pyroptosis, parthanatos, and ferroptosis. Parthanatos can be induced by DNA 
damage or reactive oxygen species (ROS) and involves overactivation of 
polyADP-ribose polymerase 1 (PARP1), the mitochondrial apoptosis inducing 
factor (AIF) and results in depletion of NAD+ and subsequently ATP49–52. 
Ferroptosis, as the name suggests, involves iron-dependent ROS production and 
lipid peroxidation due to diminished glutathione levels and reduction in 
phospholipid glutathione peroxidase 4 (GPX4) enzyme activity2,53. Lytic and 
inflammatory pyroptotic death can serve as a host defense mechanism as it is 
typically induced in immune system phagocytes, such as macrophages and 
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dendritic cells, in response to microbial infection54–56. Pyroptosis can occur upon 
recognition of pathogen proteins or DAMPs and activation of canonical 
inflammasomes and caspase-1, or intracellular lipopolysaccharide (LPS) 
recognition by inflammatory caspase-11 in mice or caspase-4 and -5 in humans. 
Inflammatory caspase activation results in cleavage of the pyroptosis executioner, 
gasdermin-D, and caspase-1-mediated processing and release of the pro-
inflammatory cytokines interleukin-1β (IL-1β) and IL-1854,55,57–60. 
Although there are some morphological differences between the various 
forms of regulated necrosis, they are thought to stimulate an inflammatory 
response due to plasma membrane leakage or rupture and exposure of 
intracellular contents (DAMPs) to the immune system. Thus, regulated necrosis is 
viewed as a more inflammatory and immunogenic death response in comparison 
to apoptosis. However, apoptotic cells may undergo secondary necrosis with 
accompanying plasma membrane leakage. This can occur if an apoptotic cell is 
not recognized and cleared, for example when excessive amounts of apoptosis 
overwhelm the phagocytosis response61,62. A recent study even implicated limited 
DAMP release via membrane permeabilization during early apoptosis63. On the 
other hand, necroptosis may dampen the inflammatory response in certain 
contexts by prematurely terminating the TNF- or LPS-driven pro-inflammatory 
cytokine and chemokine response64. Additionally, DAMP release from necroptotic 
cells was not sufficient for efficient T-cell cross-priming and tumor immunity but 
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requires additional RIPK1-dependent NF-κB-induced transcriptional responses in 
the dying cells65. 
DAMPs constitute a variety of intracellular molecules including HMGB1, 
ATP, uric acid, mitochondrial DNA, heat shock proteins (HSPs), and IL-1α66,67. 
Certain DAMPs, such as HMGB1 or ATP, are non-inflammatory and have 
important functions in cells but become immunogenic upon release from dying 
cells. Other DAMPs, such as IL-1α or IL-33, are alarmins, cytokine-like molecules 
that are typically stored in cells but can be secreted or released upon plasma 
membrane lysis67. Inflammation is the body’s response to infection or tissue 
damage, acting to neutralize a pathogen or repair injury. While pathogens can be 
detected by innate immune cells via Toll-like receptors (TLRs) and other classes 
of pattern-recognition receptors (PRRs), various DAMPs may also be sensed by 
TLRs67,68. Thus, DAMP release via cell death caused by trauma or other injury has 
the capacity to cause sterile inflammation by recruiting and activating innate 
immune cells like neutrophils and monocytes. These cells release pro-
inflammatory cytokines and chemokines, such as TNF and IL-1, leading to 
activation of lymphocytes and adaptive immunity while also recruiting additional 
innate immune cells. In addition to cytokine production, neutrophils and 
macrophages secrete ROS and various proteases that can cause cell death and 
damage tissue66,68,69. Therefore, DAMP release due to cell death and inflammation 
and immune cell activation may cooperate in feed-forward amplification loops and 
are thought to underlie the pathogenesis of many chronic inflammatory diseases. 
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Sterile inflammation has been implicated in atherosclerosis, cancer, 
autoimmune disease, Alzheimer’s, and ischemia/reperfusion injury68,69. 
Deregulation of cell death also underlies many diseases. Insufficient or excessive 
apoptosis is implicated in cancer, neurodegenerative, cardiovascular, and 
autoimmune diseases10, while secondary necrosis is linked to atherosclerosis, 
ischemia, and autoimmune disorders62. DAMP release and necroptosis have been 
linked to cancer, shock and sepsis, ischemia/reperfusion injury, inflammatory 
bowel diseases (IBD) such as Crohn’s disease, and neurodegenerative diseases 
including Alzheimer’s70. Two main pro-inflammatory cytokines, IL-1 and TNF, are 
also prominent in many diseases. IL-1 has a pathological role in rheumatoid 
arthritis, gout, cardiovascular diseases, type 2 diabetes, and hereditary 
autoinflammatory syndromes71. TNF, meanwhile, contributes to the pathogenesis 
of IBD, rheumatoid arthritis, ankylosing spondylitis, and psoriasis72. 
The intricate and interconnected network of apoptotic and necrotic cell 
death, DAMP release, and inflammation underlying disease is exemplified by the 
fact that multiple regulators are shared between these pathways. One example is 
the kinase RIPK1, a prominent decision maker downstream of both cell survival 
and cell death signals. As the rest of this thesis will examine, RIPK1 helps 
determine whether and how a cell will die, thus dictating the nature of the immune 
response and contributing to various acute and chronic diseases. 
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RIPK1 kinase and TNF receptor 1 signaling 
Overview of RIPK1 kinase structure and function 
In 1995 RIPK1 was identified as the first member of what became a family 
of serine/threonine kinases termed receptor-interacting proteins15,73. This family of 
7 RIP kinases has distinct carboxy termini but shares significant homology in the 
N-terminal kinase domain and is related to members of the interleukin-1-receptor-
associated kinase (IRAK) family involved in IL-1β and TLR signaling73,74. Murine 
RIPK1 was identified in a yeast two-hybrid screen as a 74 kDa protein (656 amino 
acids) that could interact with the intracellular DD of the Fas and TNFR1 receptors 
and was constitutively expressed in most tissues. The N-terminal region had strong 
kinase homology, while the C-terminus contained a DD that allowed for death 
receptor (DR) interaction. Interestingly, transient overexpression of RIPK1 induced 
apoptosis, and deletion of the DD abrogated this response15. RIPK1 was also 
found to interact with TRAIL-R1 (DR4) and TRAIL-R2 (DR5), death receptors for 
the cytotoxic ligand TRAIL75. Mouse and human RIPK1 have 68% sequence 
homology, with the greatest homology found in the DD, illustrating the importance 
of this domain to RIPK1 function76. 
Subsequent studies demonstrated that RIPK1 could mediate both TNF-
induced NF-κB activation76,77 and apoptosis76 by interacting with pro-survival and 
pro-death adaptor proteins TRADD76, FADD78, and TNF-receptor associated factor 
2 (TRAF2)76. RIPK1 interacts with FADD78 and TRADD via DD interactions, while 
both the kinase domain and intermediate domain (ID) can interact with TRAF276. 
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Thus, the main functional domains of RIPK1 are the N-terminal kinase domain (aa 
1-304), the ID (aa 304-553) and the C-terminal DD (aa 553-656)15,79 (Figure 1). 
RIPK1 was formally demonstrated to be a serine/threonine kinase that can 
autophosphorylate itself, but its kinase activity was not required for NF-κB 
activation since putting back a kinase-dead version into a RIPK1-deficient Jurkat 
T-cell line restored TNF-induced NF-κB signaling76,77. RIPK1 is recruited to the 
TNFR1 in a TNF-dependent manner via DD interactions with TRADD, along with 
TRAF276. Overexpression and deletion analyses showed that the ID of RIPK1 was 
required for NF-κB activation while DD overexpression was necessary and 
sufficient for apoptosis induction but could act as a dominant negative inhibitor of 
TNF-induced NF-κB activation76,77. Interestingly, caspase-8 cleaves RIPK1 at 
D324 during TNF-, Fas-, or TRAIL-mediated apoptosis. This cleavage suppresses 
NF-κB activation while increasing TNF-induced apoptosis through enhanced 
interaction with TRADD and FADD80. Thus, cleavage of RIPK1 can shift cells from 
a pro-survival to a pro-death response downstream of DR signals. 
The generation of RIPK1-deficient mice by Kelliher et al. helped clarify the 
function of RIPK1 in an in vivo setting. Surprisingly, these mice were perinatal 
lethal, succumbing within 3 days of birth with signs of lymphoid and adipose tissue 
apoptosis, suggesting that RIPK1 can inhibit cell death in vivo. Indeed, Ripk1-/- 
cells were sensitive to TNF-induced apoptosis but TNF-induced NF-κB activation 
was impaired. Meanwhile, RIPK1 was not required for Fas-induced apoptosis or 
TNF-induced JNK activation81. While RIPK1 was not essential for TNF- or Fas- 
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Figure 1. Domain structure of RHIM-dependent signaling proteins. The 
kinases RIPK1 and RIPK3 interact through their RHIM domains with each other, 
and/or with the RHIM-domain containing innate immune adaptor proteins TRIF 
and ZBP1. RIPK1 contains an intermediate (ID) and death domain (DD) while 
TRIF contains a toll-IL-1 receptor (TIR) domain. 
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induced apoptosis81, RIPK1 and its kinase activity were required for TNF-, Fas-, 
and TRAIL-induced necrotic death36. Using Ripk1-/- mouse embryonic fibroblasts 
(MEFs), RIPK1 was shown to be necessary for TNF-induced activation of the 
mitogen-activated protein kinases (MAPKs) ERK, p38, and JNK82. Interestingly, 
RIPK1 kinase activity was required for ERK but not Ikk, JNK, or p38 activation82,83. 
Thus, these early studies began to unravel the complexity of RIPK1 kinase-
dependent and kinase-independent effects on TNF-induced NF-κB and MAPK 
activation, apoptosis, and necrosis. 
Similarly, the RIP kinase family member RIPK3 was originally shown to 
induce apoptosis and NF-κB activation upon overexpression of its C-terminus84,85. 
While the N-terminal kinase domain shared homology with RIPK1, the C-terminus 
was unique and contained no DD motif. Indeed, RIPK3 was a serine/threonine 
kinase, contained autophosphorylation sites in its C-terminal domain and could 
auto-phosphorylate itself, but its catalytic activity was not required for NF-κB 
activation or apoptosis induction84–86. RIPK3 interacted with RIPK1 via it’s C-
terminus and was found to be recruited to TNFR1 upon TNF stimulation84,86. 
However, while a third study confirmed that overexpression of the RIPK3 C-
terminus could induce apoptosis, it inhibited RIPK1 and TNFR1-induced NF-κB 
activation86. It was subsequently shown that both RIPK1 and RIPK3 contain a RIP 
homotypic interaction motif (RHIM), a critical 4-amino acid (I/V)Q(I/V)G sequence 
required for RIPK1/RIPK3 interaction (Figure 1). Interestingly, while RIPK1 
phosphorylation of RIPK3 was not detected, RIPK3 could phosphorylate RIPK1, 
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leading to a reduction in TNF-induced NF-κB activation. Importantly, an intact 
RHIM was required for this RIPK3-mediated phosphorylation event and NF-κB 
inhibition87. The generation of RIPK3 knock-out mice helped clarify some of these 
early discrepancies regarding the role of RIPK3 in NF-κB activation and 
apoptosis84–88. Unlike RIPK1-deficient mice81, Ripk3-/- mice are viable, indicating 
that RIPK3 is dispensable for normal murine development88. Thymocytes from 
RIPK3-deficient mice are sensitive to various apoptotic stimuli while MEFs and 
primary bone marrow-derived macrophages (BMDMs) exhibit normal TNF- and 
LPS-induced NF-κB activation88. Therefore, RIPK3 does not appear necessary for 
NF-κB activation and apoptosis, at least in MEFs and BMDMs, and this result helps 
show the importance of studying responses in physiological settings with genetic 
knock-out mice in addition to transient overexpression systems and cell lines in 
vitro. 
While Ripk3-/- mice are viable, the perinatal lethality of RIPK1-deficient mice 
precluded the study of the physiological relevance of RIPK1 as a driver of both 
pro-survival and pro-death signals. To circumvent this issue and identify the 
lineages and cell types dependent on RIPK1 for survival, the Vandenabeele group 
and our group, in collaboration with Manolis Pasparakis, generated RIPK1 
conditional knock-out mice89,90. Upon Cre-mediated deletion of loxP sites flanking 
exon 3, a frame-shift generates a non-functional protein89. RIPK1 also has kinase-
dependent functions, especially with regards to initiating necroptotic death36,38,39. 
The small molecule necrostatin-1 (Nec-1) was found to inhibit necroptosis by 
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acting as an allosteric type III inhibitor of RIPK138,39. Nec-1 and other necrostatins 
bind to a hydrophobic, allosteric back pocket of RIPK1 near the ATP-binding site, 
thus stabilizing RIPK1 in an inactive DLG-out conformation91. While Nec-1 has 
poor metabolic stability in vivo, an optimized derivative 7-Cl-O-Nec1 (Nec1s) was 
developed with improved stability and pharmacokinetics92,93. Additionally, the 
original Nec-1 molecule was found to function as a ferroptosis inhibitor through an 
unknown mechanism94, have other off-target effects95,96, and exhibit toxicity at 
lower, but not higher, concentrations in a murine model of TNF-induced lethal 
systemic inflammatory response syndrome (SIRS)97–99. Importantly, Nec-1 is 
actually the same molecule as methyl-thiohydantoin-tryptophan (MTH-Trp), an 
inhibitor of the immune regulator indoleamine 2,3-dioxygenase (IDO)100, whose 
expression can be increased by LPS or interferon gamma (IFNγ)101. IDO activity is 
increased in patients with severe sepsis and septic shock and is associated with 
mortality102. Meanwhile, the optimized Nec-1s analog did not inhibit IDO93,99 or 
ferroptosis94 and was much more selective towards RIPK1 in comparison with the 
original Nec-1103. However, primarily Nec-1 was used in murine models to address 
the role of RIPK1 kinase activity in inflammation and cell death. Thus, in addition 
to RIPK1 conditional knock-out mice, a kinase inactive knock-in mouse model of 
RIPK1 was necessary. 
RIPK1 autophosphorylates multiple serine residues in its N-terminal kinase 
domain, including S161 in the activation segment (T-loop residues 156-196)39,91. 
The catalytic activity of many kinases is regulated by the phosphorylation status of 
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the activation segment, and phosphorylation of S161 helps re-orient and open up 
the catalytic core of RIPK139. Like most canonical kinases, RIPK1 retains the 
amino acids necessary for ATP binding and hydrolysis, including the catalytic triad 
(residues Lys45/Glu63/Asp156), the phosphate-binding loop (P-loop residues 24-
31), and the catalytic loop (residues 136-143). K45 in the ATP binding pocket binds 
to the α- and β-phosphates of ATP while the P-loop residues are associated with 
β-phosphate binding, thus helping to anchor and orient the ATP. The key catalytic 
loop HKD motif (residues 136-138) contains the catalytic base aspartate that 
initiates transfer of the γ-phosphate to the substrate serine or threonine 
residue91,104. Multiple groups mutated these key residues to generate catalytically 
inactive RIPK1 mice. GlaxoSmithKline made a K45A knock-in point mutation in 
exon 3 while our group and Genentech targeted the catalytic loop aspartate in exon 
4, generating Ripk1D138N/D138N mice40,41,105. Recently, the P-loop residues G26 and 
F27 were deleted to create a third RIPK1 kinase-dead mouse106. Unlike RIPK1-
deficient mice, all of these RIPK1 kinase inactive knock-in mice are 
viable40,41,81,105,106. The role of RIPK1 kinase activity in vitro and in vivo will be 
explored further in this thesis by utilizing the RIPK1 D138N mouse. 
 
Induction and regulation of TNF-induced NF-κB activation 
 As introduced above, RIPK1 was found to mediate TNF-induced NF-κB 
activation, but its role in the process was unclear76,77,81. Research in the last 20 
years has demonstrated the importance of ubiquitination in this signaling pathway. 
Ubiquitin is a 7kDa protein that can be covalently attached to substrate proteins as 
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a post-translational modification. Ubiquitination involves ATP-dependent ubiquitin-
activating enzymes (E1), ubiquitin-conjugating enzymes (E2) and ubiquitin ligases 
(E3). Ubiquitin is conjugated to other ubiquitin molecules at an N-terminal 
methionine (M1) to form linear ubiquitin chains or at lysine residues (K6, K11, K27, 
K29, K33, K48, and K63), thus forming monoubiquitination or polyubiquitination 
linkages on substrate proteins and affording a high degree of signaling regulation. 
For instance, K48-linked chains typically target proteins for degradation, while K11, 
K63, and linear chains act as scaffolds for recruitment and assembly of various 
signaling complexes107.  
 TNF binding initiates trimerization of the TNFR1 and assembly of signaling 
complex I, which includes the DD-containing adaptor proteins TRADD and 
RIPK176,77. TRADD recruits the E3 ubiquitin ligase TRAF2108, and is a crucial 
scaffold protein as TRADD-deficiency inhibits TNF-induced NF-κB and MAPK 
activation and apoptosis in MEFs and partially reduces signaling in BMDMs109,110. 
NF-κB subunits are sequestered in the cytoplasm in an inactive state by inhibitor 
of κB family member proteins (IκB), such as IκBα, which block the nuclear 
localization sequence (NLS). The heterodimeric IκB kinase (IKK) complex consists 
of two catalytic subunits (IKKα and IKKβ) and a regulatory subunit (IKKγ/NEMO), 
and upon TNF stimulation and activation of the IKK complex leads to IκB 
phosphorylation. This event results in K48-linked polyubiquitination and 
proteasomal degradation of the IκBs, allowing nuclear translocation of the NF-κB 
subunits and subsequent gene activation111. Importantly, both TRAF2 and RIPK1 
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recruited the IKK complex to the TNFR1, and in a kinase-independent manner 
RIPK1 could interact with NEMO and mediate IKK activation, possibly via IKK 
oligomerization112–115.  
 RIPK1 itself is polyubiquitinated in lipid rafts upon TNF stimulation116 by 
K48- and K63-linked chains, and TRAF2 was proposed as the E3 ligase that 
mediates  K63-linked RIPK1 ubiquitination83,117. RIPK1 ubiquitination may be 
required for recruitment of TGF-β activated kinase 1 (TAK1)83 that is thought to be 
the upstream regulatory kinase that phosphorylates and activates the IKK 
complex118–120. Indeed, the adaptor proteins TAK1-binding protein 2 (TAB2) and 
TAK1-binding protein 3 (TAB3) preferentially bind to K63-linked polyubiquitin 
chains, including those on RIPK1, and mutations in the zinc finger binding domain 
abrogate TAK1 kinase and subsequent IKK complex activation and NF-κB 
signaling121,122. Importantly, RIPK1 K63-linked polyubiquitination at lysine 377 
(K377) was shown to be a critical ubiquitination site for TNF-induced NF-κB 
activation. NEMO could bind K63- but not K48-linked polyubiquitin chains123, and 
a K377R mutation abolished RIPK1 polyubiquitination and could not recruit or 
activate TAK1 and NEMO/IKK complexes in a RIPK1-deficient Jurkat T-cell 
line124,125. Thus, K63-linked polyubiquitinated RIPK1 may act as a scaffold to bind 
NEMO and TAB2/3 and bring TAK1 and the IKKs into close proximity for 
phosphorylation and activation. Additionally, K63-linked ubiquitination at RIPK1 
K377 inhibits TNF-induced apoptosis through an early NF-κB-independent 
mechanism, and later in a NF-κB-dependent manner124–126. 
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 Recent studies have helped to clarify the types of ubiquitin linkages involved 
in TNF-induced NF-κB activation and the E3 ligases responsible. TRAF2 can bind 
and recruit the E3 ligases cellular inhibitor of apoptosis 1 and 2 (cIAP1 and cIAP2) 
to the TNFR1 to ubiquitylate RIPK1 and activate NF-κB signaling127,128. Small 
molecule IAP antagonists (Smac mimetics) induce auto-ubiquitination and 
proteasomal degradation of the cIAPs, resulting in TNF-induced apoptosis129,130. 
Importantly, through genetic deletion or Smac mimetic treatment, both cIAP1 and 
cIAP2 were demonstrated to be critical for TNF-induced K63-linked RIPK1 
ubiquitination and NF-κB activation and suppression of TNF-mediated 
apoptosis131–133. cIAP1 was also found to promote K11-linked polyubiquitination of 
RIPK1, and NEMO could bind to these K11-linked chains134. The linear ubiquitin 
chain assembly complex (LUBAC) mediates M1-linked linear ubiquitin chain 
formation on various TNFR1 signaling components including RIPK1 and especially 
NEMO. LUBAC consists of the adaptor proteins SHARPIN and HOIL-1, and the 
E3 ligase HOIP, and is recruited to various polyubiquitin chains conjugated by 
cIAP1/2 E3 ligase activity. LUBAC recruitment and linear ubiquitination is required 
for efficient IKK complex and NF-κB activation, and helps to inhibit apoptosis135–
140. Thus cIAP1/2 and LUBAC conjugate various polyubiquitin chains on RIPK1 
and other TNFR1 complex members to help recruit and activate the TAK1 and IKK 
kinase complexes. While TAB2/3 exclusively bind to K63-linked chains, NEMO has 
the highest affinity for M1-linked linear chains, but can also bind to K11- and K63-
linked polyubiquitin chains122,134,141,142 (Figure 2).  
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Figure 2. Signaling pathway depicting TNF-induced regulation of NF-κB 
activation and apoptosis. TNF-induced stimulation recruits TRADD, TRAF2, 
RIPK1, and cIAP1/2 to the TNFR1. E3 ligase activity by cIAP1/2 and the LUBAC 
complex adds K63- or linear (M1)-linked ubiquitin chains to RIPK1, thus 
recruiting and activating the TAK1/TAB2/TAB3 and NEMO/IKK complex, 
resulting in NF-κB and MAP kinase activation and pro-survival signaling. In the 
presence of translation inhibitors such as cycloheximide, a TRADD-dependent 
apoptotic complex IIa forms. If cIAPs, TAK1, or NEMO are inhibited or depleted, 
a RIPK1 kinase-dependent complex IIb forms, recruiting FADD and caspase-8 to 
mediate apoptosis. 
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 Although initially discovered as a mediator of TNF-induced NF-κB 
activation76,77,81,83, it seems that, depending on the cell type, loss of RIPK1 partially 
impairs TNF-induced signaling. Indeed, RIPK1-deficient MEFs, embryonic 
thymocytes and hepatocytes, and primary intestinal epithelial cells (IECs) are 
capable of activating NF-κB to varying extents in response to TNF89,90,143,144. It 
seems that in most cells RIPK1 may be required for full IKK and NF-κB activation, 
but in the absence of RIPK1, cIAP1/2 and LUBAC-mediated ubiquitination of other 
TNFR1 components can still generate a polyubiquitin scaffold necessary for 
delayed recruitment and activation of the IKK complex144. Meanwhile, the 
generation of kinase inactive RIPK1 mice has confirmed that the kinase activity of 
RIPK1 is dispensable for TNF- or LPS-induced NF-κB and MAPK activation, at 
least in MEFs and BMDMs40,41,89,105. 
 While E3 ligases and ubiquitination play a crucial role in regulating RIPK1 
and TNF-induced signaling, a class of deubiquitinating enzymes (DUBs) that 
removes various ubiquitin chains helps to fine-tune the regulation of these 
pathways107. CYLD is a DUB that removes K63- and M1-linked linear ubiquitin 
chains from RIPK1 and other TNFR1 signaling components, thus serving as a 
negative regulator of NF-κB signaling145–149. CYLD is recruited to LUBAC via the 
HOIP-binding partner, SPATA2, and similar to loss of CYLD, SPATA2 
downregulation or loss augments TNF-induced NF-κB and MAPK activation while 
suppressing apoptotic and necroptotic death induction150–153. Meanwhile, the DUB 
A20 is upregulated in response to TNF stimulation, and can remove K63-linked 
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chains while adding K48-linked chains117,154. Additionally, A20 can bind to linear 
ubiquitin chains and prevent their removal by CYLD148,149. Mice deficient in A20 
develop severe inflammation and have a shortened life-span, due to prolonged 
NF-κB activation and sensitivity to TNF-induced death154. Thus, TNF signaling is 
intricately regulated to fine-tune the pro-inflammatory and pro-survival response, 
and suppress TNF-induced apoptosis. 
Role of RIPK1 in kinase-dependent and kinase-independent apoptosis 
 TNF-induced apoptosis involves a cytoplasmic complex II formed 
sequentially after membrane-bound complex I dissociation155,156. TRADD and 
RIPK1 associate with the DD adaptor FADD and the pro-apoptotic caspase-8 in 
complex II155. The activity of complex II is typically inhibited by the catalytically 
inactive caspase-8 homolog cellular FLICE inhibitory protein (cFLIP), whose long 
(cFLIPL) and short (cFLIPS) isoforms can interact with caspase-8 to suppress 
apoptosis157. cFLIP is a key NF-κB target gene, but cycloheximide (Cx) treatment 
rapidly decreases cFLIP expression levels and sensitizes cells to TNF-induced 
apoptosis158,159. Thus, TNF-induced NF-κB activation (complex I) is a key cell 
survival checkpoint, but complex II mediated apoptosis inhibition is relieved by 
termination of NF-κB signaling, as can occur with protein synthesis inhibitors.    
 Interestingly, multiple complex II variants can form which are dependent or 
independent of RIPK1, but include at least FADD and caspase-8. Protein 
translation inhibition (Cx) combined with TNF stimulation results in the formation 
of a RIPK1-independent pro-apoptotic complex IIa which includes TRADD, FADD, 
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and caspase-8160. However, a RIPK1-dependent apoptosis-inducing complex IIb 
is formed under conditions of TNF stimulation and cIAP loss, due to knock-down 
or Smac mimetic treatment131–133,160. While cycloheximide reduces cFLIP but not 
cIAP1/2 levels, Smac mimetic treatment has the opposite effect. TNF/Smac-
induced complex IIb formation and apoptosis requires RIPK1 deubiquitination, 
RIPK1 kinase activity and CYLD while TRADD and TRAF2 are not found in the 
complex160 (Figure 2). Thus, depending on the upstream signals, TNF can 
modulate TRADD or RIPK1-dependent apoptotic complex formation.  
A separate cytoplasmic complex II initially discovered in tumor cell lines, 
termed the Ripoptosome, can form independently of death receptors in a RIPK1-
kinase dependent manner upon IAP loss/inhibition due to Smac mimetic treatment, 
genotoxic stress (etoposide treatment), or TLR3 activation. This high molecular 
weight complex (2 MDa) contains RIPK1, FADD, Caspase-8, and can include 
RIPK3 and cFLIP. Depending on the stimulus and cell type, the Ripoptosome can 
induce caspase-8 mediated apoptotic or RIPK3-mediated necroptotic death, and 
both require RIPK1 kinase activity161,162. In the absence of cIAPs, the presence 
and ratio of cFLIPL to cFLIPS isoforms regulates Ripoptosome assembly and the 
type of death induced162. FADD-bound caspase-8 recruits the cFLIP isoforms to 
heterodimerize with pro-caspase-8 molecules163. Interestingly, caspase-8 
heterodimerizes with cFLIPL, but not cFLIPS, allowing for partial caspase-8 
catalytic activity. While full proteolytic processing and apoptosis induction is 
inhibited, caspase-8 can still cleave certain substrates including RIPK1, RIPK3, 
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and CYLD to suppress necroptosis80,164–168. Indeed, Ripoptosome formation and 
cell death was inhibited in cells with low RIPK1 or high cFLIPL levels, while cFLIPS 
suppressed Ripoptosome-induced apoptosis but promoted necroptosis due to lack 
of caspase-8 activity when complexed with the short FLIP isoform162. 
In addition to cIAP1/2 loss, TAK1 or IKKα/β kinase inhibition or loss of 
NEMO also promote RIPK1 kinase activity-dependent apoptosis via NF-κB-
dependent and -independent mechanisms, both in vitro and in vivo169–173. While 
TNF/Smac mediated apoptosis required RIPK1 deubiquitination and CYLD160, 
TAK1 kinase inhibition induced complex IIb formation without affecting RIPK1 
ubiquitylation, and RIPK1-kinase dependent apoptosis was independent of 
CYLD169. Thus, recruitment of TAK1 or IKK complex members to the ubiquitin 
chains or the post-translational modifications mediated by these kinases on RIPK1, 
instead of the ubiquitin chains themselves, may sequester RIPK1 at the TNFR1 or 
by some other mechanism prevent complex IIb formation and RIPK1 kinase-
dependent apoptosis. Interestingly, mice lacking the LUBAC component SHARPIN 
due to an inactivating mutation develop severe TNFR1-driven dermatitis and multi-
organ inflammation, but all pathology is rescued by the RIPK1 kinase inactive 
K45A allele while caspase-8 heterozygosity or RIPK3/MLKL deletion rescues the 
dermatitis or partially suppresses the multi-organ inflammation, 
respectively26,27,105. Thus, like cIAPs, LUBAC presumably keeps RIPK1 in a pro-
survival state through its ubiquitination at the TNFR1. 
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The loss of RIPK1, and thus its scaffolding function, in vitro and in vivo 
provides compelling evidence for its pro-survival and anti-apoptotic roles in certain 
contexts. RIPK1-deficient or depleted MEFs or L929 cells, respectively, are 
sensitized to TNF-induced apoptosis81,174,175. TNF-stimulated RIPK1-deficient but 
not RIPK1 kinase inactive MEFs can activate apoptosis through the non-canonical 
NF-κB pathway due to degradation of TRAF2, cIAP1 and cFLIPL levels. Thus, 
RIPK1 scaffolding properties stabilize these proteins and are important to sustain 
pro-survival signaling89,176,177. Similar to MEFs, RIPK1-deficient IECs and 
organoids express reduced amounts of cIAP1, TRAF2 and cFLIP and undergo 
rapid apoptosis in vitro89. RIPK1 suppresses caspase-8 dependent apoptosis and 
RIPK3-dependent necroptosis in vivo since RIPK1-deficient mice exhibit lymphoid 
and adipose tissue apoptosis and their lethality is rescued by combined deletion 
of caspase-8 (or FADD) and RIPK3178–180. Caspase-8 loss prevents apoptosis in 
the intestine, thymus, lung, and liver of RIPK1-deficient neonates but does not 
rescue the neonatal lethality180. Additionally, IEC-specific Ripk1 knockout causes 
severe intestinal pathology and early lethality due to FADD/caspase-8-dependent 
IEC apoptosis89,90. Thus, RIPK1 serves pro-survival and pro-death roles 
downstream of TNF signaling, and can suppress or promote caspase-8-dependent 
apoptosis in a kinase-dependent and -independent manner. 
 
Mechanisms of necroptosis induction and execution 
TNF-induced necroptosis is mediated by RIPK124,39–41 and RIPK341–44 
kinase activity dependent activation of the death executioner MLKL45–48. In addition 
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to suppressing apoptosis, components of the TNFR1 signaling pathway and 
complex II repress the induction of necroptosis. Indeed, cIAP1/2, TAK1, NEMO, 
TRAF2, and A20 have all been implicated as negative regulators of necroptosis in 
vitro, and in some cases in vivo161,162,181–185. Necroptosis induction in vitro typically 
requires caspase inhibition31,36,42–44, and catalytic activity of caspase-8:cFLIPL 
heterodimers appears to suppress necroptotic activation167, potentially by cleaving 
the kinases RIPK1 and RIPK380,165. However, the strongest evidence for complex 
II mediated repression of necroptosis comes from in vivo studies.  
Genetic loss of Caspase-8, Fadd, or FLIP (cFlar gene) is lethal during 
mouse development around embryonic day 10-11 due to yolk sac vasculature 
defects186–188. Conditional caspase-8 deletion in the endothelial compartment 
phenocopies caspase-8 loss, suggesting that endothelial cell death contributes to 
the compromised yolk sac vasculature189. Interestingly, a catalytically inactive 
(C362A) but not a non-cleavable mutant (D387A) is embryonic lethal190,191, 
indicating an important role for the catalytic activity but not apoptotic function of 
caspase-8 during embryogenesis. Early embryonic lethality is driven by TNFR1 
signaling and RIPK1178,192, as their deficiencies prolong survival to E16.5 or birth, 
respectively. Co-ablation of Ripk3 or Mlkl rescues Caspase-8-/- or Fadd-/- mice to 
adulthood167,168,193–195, unequivocally demonstrating the importance of complex II 
in suppressing necroptosis in vivo during development. Additionally, FADD and 
caspase-8 also suppress RIPK3-mediated signaling to maintain adult homeostasis 
as conditional FADD or caspase-8 deletion in IECs or keratinocytes leads to 
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inflammation, cell death and tissue disruption that is rescued by RIPK3 
deficiency196–200. Interestingly, given its role in suppressing both apoptosis and 
necroptosis, embryonic lethality of cFLIP deficiency is rescued only by concomitant 
loss of both Fadd and Ripk3168. Thus, in most cases for necroptosis to ensue 
caspase-8 activity needs to be blocked. 
A necroptotic complex IIc, or necrosome, is formed when TNF and 
cycloheximide or Smac mimetic treatment is combined with pharmacologic 
caspase inhibition by using zVAD-fmk (zVAD) or other pan-caspase inhibitors43,44. 
Necrosome formation requires intact RHIM domains in RIPK1 and RIPK3, which 
allow for their stable interaction and may promote their oligomerization and the 
formation of amyloid-like fibril structures43,44,87,201. RHIM-mediated interaction may 
result in conformational changes that allow for auto- and trans-phosphorylation 
between RIPK1 and RIPK3, thus stabilizing their interaction and activating the 
necrosome43,44. RIPK3 was confirmed to be dispensable for TNF-induced NF-κB 
activation or apoptosis, but could phosphorylate RIPK1 in vitro42–44,87,88. Although 
in some cell types RIPK3 may be constitutively bound to FADD43,181, RIPK3 was 
found to be recruited to complex II when zVAD was used to block caspase-8 
activity43,44,160. Even though RIPK1 could not mediate RIPK3 phosphorylation in 
vitro, RIPK1 kinase activity is required for efficient necrosome complex formation 
and necrosome-specific RIPK3 phosphorylation, as evidenced by Nec-1 
treatment43,44,87. Thus, kinase activity and intact RHIM domains of both RIPK1 and 
RIPK3 are crucial for their interaction, necrosome formation, and subsequent 
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necroptotic cell death43,44,87 (Figure 3). Since RIPK3 can be recruited to the 
apoptotic complex II or the Ripoptosome and mediate necroptosis if caspase-8 
activity is suppressed, it is unclear if in certain cases the necrosome, forms 
independently43,44,161,162. Instead, signaling context and activation or suppression 
of various complex II components, namely caspase-8, cFLIP, FADD, RIPK1, and 
RIPK3, may determine death outcome and transition from a pro-apoptotic complex 
IIb to a pro-necroptotic complex IIc/necrosome. 
CYLD is a positive regulator of necroptosis, as knock-down or caspase-8-
mediated CYLD cleavage suppresses RIPK3-dependent cell death, while mutating 
the caspase-8 cleavage site in CYLD promotes TNF-induced 
necroptosis160,166,181,202. In vivo, CYLD loss was able to partially suppress RIPK3-
triggered inflammation and cell death in FADD-deficient IECs and 
keratinocytes196,197. Interestingly, CYLD may not regulate RIPK1 ubiquitination in 
complex I but in the necrosome, as CYLD loss resulted in increased RIPK1 
ubiquitination in the necrosome and impaired RIPK1 and RIPK3 phosphorylation. 
RIPK3 may also be polyubiquitinated in the necrosome, but CYLD deficiency 
attenuated TNF/zVAD- but not TNF/Cx/zVAD- or TNF/Smac/zVAD-induced 
necroptosis43,203. Thus, CYLD activity supports necroptosis but is not essential for 
it to occur in all signaling contexts or cell types. 
TNF-induced necroptosis can trigger downstream ROS181,204, and RIPK3 
was found to help activate metabolic enzymes and regulate TNF-induced ROS 
production42,44. Indeed, it was thought that ROS production may be the mechanism  
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Figure 3. Signaling pathways depicting the mechanism and regulation of 
necroptosis induction and execution. Necrosome formation occurs 
downstream of TNFR1, TLR3, and TLR4 receptors and the cytosolic innate 
immune sensor ZBP1 (DAI). In conditions of caspase inhibition (zVAD), RIPK1 and 
RIPK3 interact via their RHIM. Upon RIPK1 and RIPK3 interaction and kinase 
activation, the necroptosis executioner MLKL is recruited to RIPK3 and activated. 
TLR3 and TLR4 mediate necrosome formation via the RHIM-containing adaptor 
TRIF binding to RIPK3; the role of RIPK1 is context and cell-type dependent. When 
ZBP1 senses virus or dsDNA, it can recruit RIPK3 via its RHIM to mediate MLKL 
activation and necroptosis. RIPK1 blocks this ZBP1/RIPK3 interaction by an 
unknown mechanism. 
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of necroptosis execution. The mitochondrial phosphatase phosphoglycerate 
mutase family member 5 (PGAM5) and the mitochondrial fission factor dynamin-
related protein 1 (Drp1) were reported to contribute to necroptosis as downstream 
effectors by causing mitochondrial fragmentation205. However, numerous 
subsequent studies, both in vitro and in vivo, have demonstrated that PGAM5, 
Drp1, ROS, and even mitochondria themselves, are dispensable for necroptosis 
to ensue47,206–210. Thus, cellular ROS may accompany necroptosis due to 
membrane rupture and/or cell stress, but is not required for its execution. 
 The pseudokinase MLKL, activated by RIPK3-mediated phosphorylation, is 
considered the sole effector necessary for necroptosis execution as demonstrated 
by the generation of Mlkl-/- mice47,48. Initially identified in small molecule and shRNA 
screens, RIPK3 phosphorylates human MLKL on T357 and S358 and mutation of 
both sites blocks necroptosis but doesn’t affect necrosome formation45,46. The 
small molecule necrosulfonamide (NSA) blocks necroptosis execution 
downstream of RIPK3 activation by targeting specifically human MLKL. 
Interestingly, there is a basal RIPK3/MLKL interaction in some cell types, but MLKL 
recruitment and increased binding is dependent on RIPK3 kinase activity and 
phosphorylation of human RIPK3 at S22746. Similarly, TNF-induced 
phosphorylation of murine RIPK3 at T231 and S232 is essential for MLKL 
recruitment to the necrosome but not for initial necrosome assembly211,212. 
Meanwhile, RIPK3-mediated MLKL phosphorylation, while crucial for necroptosis 
signaling, is dispensable for stable RIPK3/MLKL complex formation212. 
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Interestingly, mutations in the MLKL pseudoactive site result in constitutive, 
RIPK3-independent necroptosis47. 
 MLKL consists of an N-terminal four-helix bundle domain connected to a C-
terminal pseudokinase domain by a two-helix linker, or brace, region47,212. The 
kinase-like domain lacks the P-loop and several other key residues, so even 
though it can bind ATP, MLKL is catalytically inactive46,47. Phosphorylation of MLKL 
activation loop residues by RIPK3 results in a conformational shift which exposes 
the four-helical bundle domain of MLKL by alleviating its restraint by the C-terminal 
pseudokinase domain47,212,213. MLKL oligomerizes and translocates to cellular 
membranes, where the 4-helix bundle domain acts as the necroptosis executioner 
by causing membrane permeabilization213–218. Indeed, expression of the 4-helix 
bundle domain alone or with the two-helix linker results in constitutive 
necroptosis213,216,218. However, the oligomeric state of MLKL, and whether MLKL 
mediates necroptosis by directly forming pores or through activation of ion 
channels remains a matter of on-going study. MLKL has been reported to form 
trimers, tetramers, and even octamers215,216,219. One group found that MLKL 
interacts with a cation channel (TRPM7) to cause calcium influx, while another 
showed tetramerized MLKL translocates to lipid rafts and causes sodium 
influx215,216. Recently, MLKL was demonstrated to form cation channels that are 
preferentially permeable to magnesium instead of calcium220. Meanwhile, others 
have implicated a direct permeabilization mechanism by oligomerized MLKL 
binding to negatively charged membrane phosphatidylinositol 
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phosphates217,218,221. Overall, RIPK3-mediated activation and phosphorylation of 
MLKL results in exposure of the MLKL 4-helical bundle domain and oligomerization 
and translocation to the plasma membrane where it mediates, directly or indirectly, 
pore formation and causes necroptotic death of the cell. 
 In certain in vitro contexts, necroptosis can actually proceed independently 
of RIPK1. In MEFs that overexpress RIPK3, TNF can, in a TRADD-dependent 
manner, mediate necroptosis in the absence of RIPK1222. In L929 cells, TNF-
induced necroptosis via RIPK3 occurs upon knock-down of caspase-8 and 
RIPK1175. Similarly, in L929 cells and MEFs, RIPK1 knock-down was found to 
potentiate TNF-induced necroptosis when caspase-8 is inhibited with zVAD223. 
Thus, at least in some contexts, RIPK1 may suppress RIPK3 activation by 
inhibiting RIPK3 activation and oligomerization. Three groups utilized artificial 
dimerization systems to assess the role of RIPK1 and RIPK3 oligomerization in 
necroptosis induction irrespective of upstream death receptor signaling224–226. One 
study found that induced RIPK1 or RIPK3 dimerization could induce either 
apoptosis or necroptosis, although RIPK3-induced apoptosis didn’t require its 
kinase domain. This suggests that the mode of death is determined by the relative 
availability of caspase-8, FADD, and MLKL224. Meanwhile, the other studies 
showed that the RIPK1/RIPK3 hetero-dimer recruits additional free RIPK3 into the 
amyloid scaffold to induce RIPK3 autophosphorylation and propagate the 
necroptotic signal, but RIPK1 can act to suppress spontaneous cytosolic RIPK3 
activation by controlling its oligomerization225,226.  
32 
 
 
 
 Surprisingly, mice expressing a kinase dead RIPK3 D161N are embryonic 
lethal at E10.5, similar to mice deficient in complex IIb components186–188,227. The 
mice succumb to massive apoptosis, and are rescued by RIPK1 or caspase-8 
deficiency, although the apoptotic death in this context does not require RIPK1 
kinase activity but rather scaffolding function to recruit FADD and caspase-841. 
Interestingly, three small-molecule inhibitors of RIPK3 kinase activity show 
concentration-dependent apoptosis sensitization by a similar RHIM-driven 
recruitment of RIPK1 and subsequent assembly of a caspase-8/FADD/FLIP 
complex228. However, RIPK3K51A/K51A kinase inactive mice are viable and healthy, 
suggesting that the D161N mutation or RIPK3 inhibitors induce a conformational 
change that exposes the RHIM for binding with RIPK1 to promote pro-apoptotic 
complex activation228. Indeed, oligomerized RIPK3 induces apoptosis in MLKL-
deficient cells224. These studies portray an intricate regulatory network of complex 
II components and the decision to undergo apoptotic or necroptotic death, with 
multiple complex members exhibiting pleiotropic function.  
 
Post-translational modifications regulate RIP Kinase signaling  
Additional regulation of complex II members, especially RIPK1 and RIPK3, 
is mediated by post-translational modifications, namely phosphorylation and 
ubiquitination, that affect the stability of necrosome components. Heat shock 
protein 90 (HSP90) is a chaperone molecule that regulates the stability and 
function of various cellular proteins. RIPK1 is one such HSP90-associated protein 
since inhibition of HSP90 function results in proteasomal degradation of 
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RIPK1174,229. RIPK3 also associates with the HSP90-CDC37 cochaperone 
complex, and this interaction is required for binding to RIPK1 and necroptotic 
RIPK3 activation230. Indeed, HSP90 inhibitors were protective in a rat model of 
TNF-induced SIRS. Interestingly the RIPK3/HSP90 interaction was observed in 
human and rat but not mouse cells230. A reported mechanism of modulating RIPK3 
stability is via the E3 ligase CHIP, which ubiquitylates RIPK3 and targets it for 
lysosomal degradation. CHIP deficiency increases RIPK3 expression levels and 
necroptosis sensitivity. Chip-/- mice die a few weeks after birth due to inflammation 
and cell death in the small intestine, but this phenotype is rescued by concomitant 
RIPK3 ablation231. Thus, CHIP may be a negative regulator of necrosome 
formation and necroptotic death. HSP90 has also been reported to modulate MLKL 
stability, oligomerization, and membrane translocation, thus potentially acting on 
RIPK1, RIPK3, and MLKL to regulate necrosome stability and enhance TNF-
induced necroptosis232–234. MLKL may also be constitutively associated with 
TRAF2, while TNF stimulation and CYLD-dependent TRAF2 deubiquitination is 
required for their dissociation. Thus, TRAF2 potentially serves as a necroptosis 
suppressor in vitro and in vivo183. 
Phosphorylation of RIPK1 and RIPK3, mediated by several complex I 
components, helps fine-tune the TNF-induced response via positive and inhibitory 
phosphorylation events. Although mutating most individual serine residues in the 
RIPK1 kinase domain has minimal effect on RIPK1 kinase activity and TNF-
induced necroptosis induction, a RIPK1 S89A mutant enhances both. Meanwhile, 
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a phosphomimetic RIPK3 S204D mutant caused necroptosis insensitive to Nec-1 
inhibition235. TAK1 transiently phosphorylates RIPK1 at S321 in response to TNF 
stimulation. This does not affect NF-κB activation, but blocking this 
phosphorylation promotes RIPK1 kinase-dependent apoptosis. Interestingly, 
sustained TAK1-mediated phosphorylation of multiple RIPK1 residues, including 
S321, promotes RIPK1 kinase-dependent necroptosis236. The kinases IKKα and 
IKKβ phosphorylate RIPK1 to suppress RIPK1-mediated apoptosis and 
necroptosis downstream of TNF signaling in an NF-κB-independent manner. This 
phosphorylation occurs in complex I, and in vivo inhibition of the IKKs sensitizes 
mice to RIPK1 kinase-dependent death in a model of TNF-induced SIRS171. 
However, the IKK complex does not seem to mediate RIPK1 S321 
phosphorylation236. Instead, this phosphorylation may be mediated by MAPKAP 
kinase-2 (MK2), a kinase induced downstream of TNF or LPS signaling by TAK1-
mediated activation of p38, independently of the IKK complex237–239. MK2 
phosphorylates primarily cytosolic RIPK1 at S320/S321 and S335/S336 
(human/mouse), and this inhibits RIPK1 kinase activation and helps prevent 
complex II formation and apoptosis/necroptosis when combined with inhibitory 
IKK-mediated phosphorylation of RIPK1 in complex I. Interestingly, it seems that a 
cytosolic RIPK1 pool contributes to complex II formation with complex I dissociated 
RIPK1237–239. Similar to IKK inhibition, an MK2 inhibitor sensitizes mice to TNF-
induced SIRS in a RIPK1 kinase-dependent manner237. Finally, RIPK3 
phosphorylation may be modulated by the phosphatase Ppm1b acting to limit 
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RIPK3 activation via T231 and S232 auto-phosphorylation, thus suppressing 
MLKL recruitment and necroptosis induction in vitro and in vivo. Ppm1b loss of 
function mice were sensitized to TNF-induced caecum damage and SIRS via 
RIPK3 activation240. 
Ubiquitination of various TNF signaling components also affects their 
activation status and helps regulate their function. For instance, RIPK1 is modified 
with linear and K63 ubiquitin chains in the necrosome, while RIPK3 contains K63 
and K48-linked chains184,203,231,241,242. RIPK3 is K63-ubiquitinated at lysine 5 (K5) 
in the necrosome, helping to support RIPK1/RIPK3 complex formation. This event 
is modulated by A20, as it deubiquitinates the RIPK3 K5 residue, thus negatively 
regulating necrosome formation and necroptosis. A20-deficient T cells and MEFs 
are susceptible to RIPK3-mediated necroptosis due to enhanced necrosome 
formation. Indeed, RIPK3 deletion rescues the inflammation and significantly 
prolongs the survival of A20-/- mice184. However, while a separate study 
demonstrated that RIPK3 deficiency or catalytically inactive RIPK1 delay lethality 
of A20-deficient mice, MLKL deficiency had no protective effect227. Thus, RIPK3-
dependent signaling but not necroptosis contributes to the lethality of A20-deficient 
mice. Meanwhile, K63-linked RIPK1 ubiquitination in the necrosome is not 
mediated by cIAP1/2, but M1-linked ubiquitination seems to be mediated by 
LUBAC241. RIPK1 ubiquitination in the necrosome also requires RIPK1 kinase 
activity, while RIPK3 and MLKL are dispensable242. Mutating a necroptosis-
associated ubiquitination site (K115R) reduced RIPK1 ubiquitination and 
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phosphorylation, thus disrupting necrosome assembly and induction of 
necroptosis. This suggests that RIPK1 ubiquitination in the necrosome contributes 
to maintaining RIPK1 kinase activation and necrosome formation. The K115R 
mutation had no effect on RIPK1 ubiquitination at complex I or TNF-induced NF-
κB activation242. Interestingly, a recent study implicated the E3 ligase Pellino 1 
(PELI1) in mediating K63-linked ubiquitination of RIPK1 at K115 during 
necroptosis. This ubiquitination also required RIPK1 kinase activity and PELI1 
promoted RIPK1 activation and necrosome assembly243. Thus, coordinated RIPK1 
phosphorylation and ubiquitination in the necrosome seems to contribute to the 
regulation of necroptosis signaling. While tremendous progress has been made, 
these studies convey the complexity of regulation and pleiotropy of TNFR1 
signaling components, and raise more questions regarding how cells decide to 
undergo apoptosis or necroptosis. 
 
Toll-like receptors and necroptosis 
Toll-like receptor signaling and the RIP kinases in innate immunity 
 The TLR family of PRRs play an important role in innate immunity, as the 
TLRs are critical for sensing and responding to various pathogens and pathogen-
associated molecular patterns (PAMPs) outside the cell or in endosomes. TLRs 
have an extracellular leucine-rich repeat (LRR) segment which allows for distinct 
ligand recognition. TLRs involved in recognition of microbial components (such as 
TLR2, TLR4, and TLR6) are located at the plasma membrane. Meanwhile, TLRs 
involved in nucleic acid recognition (e.g. TLR3, TLR7, and TLR9) are localized to 
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the endosomal membrane. The TLRs contain a cytoplasmic Toll/IL-1R (TIR) 
homology domain which recruits TIR domain-containing adaptors to propagate 
downstream signaling cascades activating NF-κB, MAPK, and interferon (IFN) 
pathways. Myeloid differentiation primary response 88 (MyD88) is the most 
universal of the 5 TIR adaptors, mediating signaling downstream of various TLRs 
except for TLR3244. 
 TLR3 recognizes virus-derived or synthetic poly(I:C) double-stranded RNA 
(dsRNA) while TLR4 is activated upon LPS binding245–247. Stimulation of these two 
receptors activates NF-κB, MAPK, and IFN responses via MyD88-independent 
pathways through TIR-domain-containing adaptor-inducing IFN-β (TRIF)248–251. 
TRIF is directly recruited to TLR3 but associates with TLR4 through the TRIF-
related adaptor molecule (TRAM)252,253. Analysis of TRIF-deficient mice 
demonstrated that TLR3/4-induced interferon regulatory factor 3 (IRF3) activation 
and downstream IFN signaling requires TRIF while TLR-induced NF-κB activation 
can proceed downstream of TLR4 but not TLR3 via the MyD88-dependent 
pathway254,255. Interestingly, the C-terminus of TRIF contains a RHIM, allowing it 
to bind to RIPK1 and RIPK3256 (Figure 1). RIPK1 mediated the TRIF-dependent 
NF-κB activation induced by TLR3 and TLR4 but was dispensable for IRF3 
activation and the IFN response. RIPK1 was also phosphorylated and 
ubiquitinated in TLR3-stimulated cells, while RIPK3 inhibited TRIF-induced NF-κB 
activation by competing for binding to RIPK1256,257. Thus, TRIF recruits RIPK1 via 
RHIM interaction to activate NF-κB signaling downstream of TLR3 or TLR4. 
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 The cytoplasmic DNA sensor Z-DNA binding protein 1 (ZBP1), also known 
as DAI (DNA-dependent activator of IFN-regulatory factors), is an IFN-inducible 
sensor that can bind dsDNA and activate IFN and NF-κB signaling258,259. 
Interestingly, ZBP1 contains two RHIM sequences, and recruits both RIPK1 and 
RIPK3 to activate NF-κB in a RHIM-dependent manner259,260 (Figure 1). This 
ZBP1-induced signaling is disrupted by the murine cytomegalovirus (MCMV) M45-
encoded viral inhibitor of RIP activation (vIRA), which contains a RHIM and acts to 
suppress RIPK1-dependent TNF-induced signaling and necroptosis during 
infection261,262. Thus, viral proteins can inhibit pro-inflammatory and cell death 
signaling via RHIM-dependent interactions with host proteins RIPK1 and RIPK3. 
 
Other stimuli that induce necroptosis  
 TRIF and ZBP1 interaction with RIPK1 and/or RIPK3 via RHIM can mediate 
necroptosis instead of proinflammatory signaling when caspase function is 
inhibited. For instance, during MCMV infection ZBP1 interacts with RIPK3 via 
RHIM and activates MLKL to mediate virus-induced necroptosis in a RIPK1-
independent manner while the RHIM-containing MCMV vIRA suppresses 
necroptosis induction by interfering with ZBP1/RIPK3 complex formation263,264. 
Surprisingly, genetic evidence demonstrated that ZBP1 drives RIPK3/MLKL-
mediated necroptosis in Ripk1-/- mice, indicating that RIPK1 maintains 
developmental homeostasis by acting via its RHIM to suppress ZBP1-mediated 
activation of RIPK3265,266. Thus, ZBP1-driven necroptosis requires RIPK3 and 
MLKL but proceeds independently of RIPK1. 
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 If caspases are inactivated, TRIF mediates necroptosis via RHIM-
dependent RIPK1/RIPK3 recruitment downstream of poly(I:C) or LPS stimulation 
of TLR3 and TLR4. RIPK1 kinase activity seems to be required for necroptosis in 
macrophages but is dispensable for TLR3-induced necroptosis in fibroblast and 
endothelial cell lines267,268. Type I (IFNα/IFNβ) or type II (IFNγ) interferons induce 
necroptosis in FADD-deficient or caspase-inhibited MEFs in a RIPK1- and RIPK3-
dependent manner. Interferons transcriptionally upregulate the RNA-responsive 
protein kinase R (PKR) in MEFs to interact with RIPK1 and mediate necrosome 
formation178,269. Surprisingly, RIPK1-deficient primary MEFs are sensitized to 
poly(I:C) or interferon-mediated RIPK3-dependent necroptosis without the need 
for caspase inhibition, and TRIF or IFNαR ablation prolongs survival of Ripk1-/-
/Tnfr1-/- mice178, revealing that RIPK1 can potentiate or repress TLR and IFN-
induced necroptosis. In macrophages however, LPS, poly(I:C), or TNF-induced 
necroptosis in the presence of caspase inhibitors requires type I IFN signaling but 
PKR is dispensable270. A type I IFN-induced IRF9/STAT1/STAT2 complex leads 
to sustained RIPK1 and RIPK3 phosphorylation and necrosome activation, thus 
promoting TLR/TRIF- or TNF-induced necroptosis270. MLKL appears to be an 
interferon-stimulated gene178,269,271, thus clarifying how interferons prime 
macrophages and increase their sensitivity to LPS- and TNF-induced necroptosis. 
Macrophage necroptosis, therefore, incorporates interferon, TLR/TRIF, and TNF-
induced signaling to mediate death. 
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Cross-talk between inflammation and cell death in mediating disease 
RIPK1 death-independent roles in pro-inflammatory signaling 
 In addition to its role in mediating NF-κB activation or cell death in response 
to TNF stimulation, additional RIPK1 death-independent effects on 
cytokine/chemokine production have recently emerged. In LPS-stimulated bone 
marrow-derived dendritic cells (BMDCs), RIPK3 assembles a complex with FADD, 
caspase-8, and RIPK1 to mediate pro-IL-1β processing. This effect does not 
depend on the kinase activities of RIPK1 or RIPK3272. In caspase-8-deficient DCs, 
RIPK1 kinase activity but not RIPK3 drives systemic autoimmunity by hyper-
responsive TLR4/7/9-induced proinflammatory cytokine secretion273. Interestingly, 
a separate study reported RIPK1 kinase activity, RIPK3, and MLKL-dependent 
LPS-induced inflammasome activation and IL-1β secretion in caspase-8-deficient 
DCs, occurring independently of necroptosis274. cIAP loss in macrophages 
activates RIPK1 kinase-dependent TNF transcription and RIPK3-dependent TNF 
secretion in an MLKL-independent manner, leading to enhanced proinflammatory 
cytokine production275. Indeed, RIPK1 kinase activity in several cell lines, including 
L929 cells, was shown to regulate TNF production upon caspase inhibition, though 
a potential role for RIPK3 in this context has not been addressed39,103,276. RIPK1 
has also been reported to regulate TNF/zVAD or LPS/zVAD-induced cytokine 
responses in BMDMs in vitro and in vivo, in a kinase-dependent but necroptosis-
independent manner24,277,278. Furthermore, IL-1α production and autoinflammation 
in a SHP-1 mutant mouse (Ptpn6spin) is mediated by RIPK1 kinase independently 
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of RIPK3279. Depending on the context and cell type, RIPK1 and/or RIPK3 can 
mediate inflammatory signaling in a kinase-dependent or kinase-independent 
manner. Thus, the pleiotropy of RIPK1 makes it challenging to unravel the 
contribution of RIPK1 scaffolding or kinase function to inflammatory or cell death 
processes in the context of infection or disease.  
 
Necroptosis in disease models 
 RIPK1- and RIPK3-driven inflammation and/or necroptosis have been 
implicated in various mouse models of disease or infection, but only recently have 
we begun to discern differences between inflammatory or cell death contribution 
through the use of MLKL-deficient mice. Many viruses encode caspase inhibitors, 
so necroptosis can act as a host defense mechanism in case apoptosis is 
suppressed. Indeed, RIPK3-induced necroptosis in Vaccinia virus-infected cells 
suppresses inflammation and helps control infection in vivo43. Similarly, MCMV-
encoded vIRA targets DAI and RIPK3 via RHIM to disrupt their interaction and 
suppress virus-induced necroptosis263,264. Herpes simplex viruses (HSV) HSV-1 
and HSV-2 encode RHIM-containing proteins that are bound by RIPK1 and RIPK3 
to induce necroptosis and restrict viral propagation in mice280. Interestingly, these 
HSV-encoded proteins suppress necroptosis induction in human cells280,281. 
Meanwhile, infection with Influenza A virus (IAV) results in activation of both 
apoptosis and necroptosis to limit viral replication upon sensing by ZBP1. ZBP1 
activation of RIPK3 mediates both RIPK1/FADD/caspase-8-dependent apoptosis 
and RIPK3/MLKL-dependent necroptosis in infected cells282–284.  
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 Bacteria can also modulate the type of cell death induced during infection. 
RIPK1, RIPK3 and caspase-8 in macrophages activate NF-κB and caspase-1-
mediated inflammasome signaling and induce apoptotic and pyroptotic cell death 
to help control Yersinia pestis infection and regulate host resistance285,286. If 
caspases are inhibited, RIPK1 and RIPK3 mediate necroptotic death of infected 
cells285,286. Interestingly, enteropathogenic Escherichia coli (EPEC) secretes the 
cysteine protease EspL during infection to cleave all RHIM-containing host 
proteins, thus inhibiting host-mediated inflammatory and necroptotic responses287. 
Infection with Salmonella enterica serovar Typhimurium induces cell death by type 
I IFN-driven RIPK1/RIPK3-mediated macrophage necroptosis although RIPK3-
deficiency did not provide a survival advantage in vivo288. Thus, depending on the 
cause of infection, viral or bacterial-induced necroptosis can be detrimental to the 
host or serve as a defense mechanism. 
 Although genetic evidence supports the role of RIPK1 in suppressing 
caspase-8-mediated apoptosis and RIPK3/MLKL-mediated necroptosis178–180, 
RIPK1 and RIPK3 have been implicated in mediating inflammation and necroptosis 
in various diseases including shock, ischemia-reperfusion, and neurodegenerative 
diseases289,290. RIPK3, MLKL, and RIPK1 kinase inactivity (by Nec-1 inhibition) 
have been shown to drive TNF-induced hypothermia, shock, and lethality, thus 
implicating necroptosis in shock and sepsis97,227. Nec-1 was originally shown to be 
protective in a model of ischemia-reperfusion injury in the brain38. Subsequently, 
various studies have implicated RIPK1 kinase activity and RIPK3 as protective in 
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models of heart and kidney ischemia-reperfusion injury291–293. However, MLKL-
deficient mice were recently shown to be less resistant to kidney ischemia-
reperfusion injury, thus raising questions regarding the overall contribution of 
necroptosis to this model227. Interestingly, necroptosis may play an important part 
in neurodegeneration, as RIPK1, RIPK3, and MLKL expression and activation is 
elevated in pathological samples of patients with multiple sclerosis or ALS294,295. 
Thus, while RIPK1 contributes to various diseases, it will be important to discern 
between the contribution of inflammation and cell death in future studies of these 
disease models. 
 An open question in the cell death field is the physiological relevance of 
necroptosis in normal biology. As discussed above, RIPK1/RIPK3-mediated 
inflammation and MLKL-dependent necroptosis are being actively studied and 
implicated in various pathophysiological conditions of mouse and human infection 
and disease. However, does necroptosis have a role during development or 
organismal homeostasis, like caspase-8 does with organ and body formation and 
regulation of cell populations? The viability of RIPK1 kinase inactive, Ripk3-/- and 
Mlkl-/- mice suggests that necroptosis is dispensable for murine development and 
normal homeostasis under non-challenged conditions40,41,47,48,88,105. Indeed, 
necroptosis is typically observed in vitro or in mouse models in vivo only under 
conditions of inhibition or deletion of the upstream negative regulators like cIAP1/2, 
FADD, caspase-8, TAK1, or NEMO. Thus, current data argue that necroptosis is 
actively suppressed during development and under steady state conditions, but 
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improved biomarkers and additional experimental techniques will be needed to 
fully address whether necroptotic death has a physiological role during 
development or organismal homeostasis. 
In this thesis, I focus on defining and elucidating the role of RIPK1 kinase 
activity in mediating inflammatory and death responses. Specifically, in chapters 2 
and 3 I address the role of RIPK1 kinase activity in TNF- or LPS-induced 
transcriptional and translational cytokine/chemokine responses and the induction 
of necroptotic complex formation and death in vitro. Utilizing RIPK1 kinase inactive 
mice, I elucidate the contribution of RIPK1 kinase activity to inflammatory and cell 
death processes in a mouse model of TNF-induced shock in chapters 3 and 4. 
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CHAPTER II 
 
 
 
RIPK1 kinase activity mediates necroptotic complex 
formation and death in vitro 
 
 
 
 
 
*Data in this chapter are unpublished or were originally published in The Journal 
of Immunology. Polykratis A, Hermance N, Zelic M, Roderick J, Kim C, Van TM, 
Lee TH, Chan FKM, Pasparakis M and Kelliher MA. 2014. Cutting edge: RIPK1 
Kinase inactive mice are viable and protected from TNF-induced necroptosis in 
vivo. J Immunol. 193(4):1539-1543. Copyright © [2014] The American Association 
of Immunologists, Inc. 
 
*All experiments and data analysis in Figures 4 to 7 were performed by Matija Zelic 
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Introduction 
RIPK1 plays a prominent role in proinflammatory and cell survival signaling 
by mediating optimal NF-κB and MAP kinase pathway activation downstream of 
TNFR1 and TRIF-dependent TLRs. In addition to pro-survival signaling, RIPK1 
can induce caspase-8 dependent apoptosis or caspase-independent necroptosis. 
Under conditions of caspase inhibition, the related RIPK1 and RIPK3 kinases 
interact through their RHIMs, resulting in auto- and trans-phosphorylation and 
RIPK3-mediated phosphorylation of the downstream pseudokinase MLKL. 
Phosphorylation of MLKL results in its oligomerization and translocation to the 
plasma membrane. Activated MLKL mediates membrane permeabilization and 
necroptosis, leading to the release of DAMPs. Necroptosis requires the kinase 
activities of RIPK1 and RIPK3 and can be activated downstream of death receptors 
(TNF, FAS, TRAIL), TLRs 3 and 4, type I or II interferon receptors (IFNαR or 
IFNγR) and the cytosolic viral sensor ZBP1289,290.  
Although reported to be dispensable for TNF/Cx-induced apoptosis, 
TNF/Smac-induced complex IIb formation and apoptosis induction was shown to 
depend on RIPK1 kinase activity in HT29 cells160. Meanwhile, necrosome 
(complex IIc) formation required intact RIPK1 and RIPK3 RHIM domains and 
kinase activity in cells treated with TNF and zVAD combined with either 
cycloheximide or Smac mimetics43,44. Since RIPK1 kinase-dependent effects were 
interrogated with in vitro reconstitution studies or using the small molecule inhibitor 
of RIPK1 kinase activity, Nec-138,39, interpretation of these studies is limited by 
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compound instability and off-target effects99. Additionally, necroptosis can proceed 
independently of RIPK1 in certain cell types, as RHIM-containing ZBP1 or TLR3/4 
adaptor TRIF can directly interact with RIPK3264,267,268. To determine the 
contribution of RIPK1 kinase activity to development and tissue homeostasis in 
vivo, we generated knock-in mice expressing a kinase-inactive mutant RIPK1 from 
the endogenous Ripk1 locus. We replaced the conserved aspartate (D) at position 
138 within the activation loop of the RIPK1 kinase domain with asparagine 
(Ripk1D138N), thus rendering the mice catalytically inactive40. Unlike RIPK1-
deficient mice, and similar to RIPK3 and MLKL-deficient mice, these RIPK1 D138N 
knock-in mice were viable and allowed us to re-assess the role of RIPK1 kinase 
activity in complex II formation and cell death regulation40,47,48,81,88. Utilizing MEFs 
and primary bone marrow-derived macrophages from these mice, we demonstrate 
the requirement for RIPK1 kinase activity in necrosome formation and in TNF- or 
LPS-induced necroptosis. 
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Results 
RIPK1 but not RIPK3 kinase activity is required for necroptotic complex 
formation in MEFs  
 The kinase activities of both RIPK1 and RIPK3 have been implicated as 
necessary for stable necrosome complex formation and induction of necroptotic 
death43,44. To address the role of RIPK1 kinase activity using endogenous kinase 
inactive protein instead of chemical inhibitors, we immortalized MEFs from WT, 
Ripk1D138N/D138N, and Ripk3-/- mice. We found that RIPK3 and the kinase activity of 
RIPK1 are required for stable RIPK1/RIPK3 interaction and necrosome formation 
upon TNF/Smac/zVAD stimulation (Figure 4A). Complex formation was rapid, as 
we could detect a RIPK1-RIPK3 interaction as early as 1-2 hours after 
TNF/Smac/zVAD stimulation. As expected, TNF/Smac treatment, a pro-apoptotic 
stimulus, did not induce a RIPK1/RIPK3 interaction. Interestingly, inhibition of 
RIPK3 kinase activity with GSK843A or GSK872B seemed to potentiate 
RIPK1/RIPK3 interaction and necrosome formation (Figure 4B) while addition of 
Nec-1 or GSK963A, two RIPK1 kinase inhibitors, blocked RIPK1/RIPK3 
interaction. Perhaps GSK843A and GSK872B stabilize RIPK3 in a kinase inactive 
formation with RIPK1, thus blocking MLKL recruitment and activation, thereby 
sustaining the RIPK1/RIPK3 interaction. Indeed, RIPK1 in the whole cell lysate 
migrates as two bands only in instances of RIPK1/RIPK3 complex formation, with 
the slower migrating band typically indicative of phosphorylation (Figure 4). 
Although we did not test this hypothesis directly with the addition of phosphatase,  
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RIPK1 may be phosphorylated upon TNF/Smac/zVAD treatment in the absence of 
RIPK3 kinase activity (Figure 4).   
While we could not detect caspase-8 above the Ig heavy chain band in this 
complex (Figure 4A), immunoprecipitating caspase-8 in TNF/Smac/zVAD-treated 
cells revealed a RIPK1/RIPK3/caspase-8 interaction that required RIPK1 but not 
RIPK3 kinase activity for complex formation (Figure 5A). Protein levels seemed to 
decrease in the whole cell lysate upon complex formation, suggestive of 
necrosome aggregation into a buffer-insoluble fraction (Figure 5A). Interestingly, 
the N-terminal FLIPL fragment FLIP(p43), processed by caspase-8, was increased 
upon stable complex formation (Figure 5B). FLIP(p43) blocks procaspase-8 
cleavage but unlike FLIPL allows for caspase-8/RIPK1 interaction296,297. Overall, 
our results indicate that the kinase activity of RIPK1, but not RIPK3, is required in 
MEFs for stable necrosome formation and RIPK1/RIPK3 interaction upon 
treatment with the pro-necroptotic TNF/Smac/zVAD stimulus. 
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Figure 4. RIPK1, but not RIPK3, kinase activity is required in MEFs to mediate 
a stable RIPK1/RIPK3 interaction in response to a pro-necroptotic stimulus. 
WT, Ripk1D138N/D138N and Ripk3-/- SV40-immortalized MEFs were pre-treated with 
Smac and/or zVAD for 1 hour (A) or additional RIPK1 and RIPK3 kinase inhibitors 
(B), before treating with TNF for 2 hours. A representative western blot showing 
protein lysates from RIPK3 immunoprecipitates or whole cell lysate probed with 
antibodies to RIPK1, RIPK3, or caspase-8 is depicted. 
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Figure 5. Efficient necrosome formation in response to TNF/Smac/zVAD 
stimulation in MEFs requires the kinase activity of RIPK1 but not RIPK3. WT, 
Ripk1D138N/D138N and Ripk3-/- SV40-immortalized MEFs were pre-treated with 
Smac, zVAD, and RIPK1 and RIPK3 kinase inhibitors for 1 hour (A) prior to 
treatment with TNF for 2 hours. Representative western blots depict protein lysates 
from caspase-8 immunoprecipitates or whole cell lysate probed with antibodies to 
RIPK1, RIPK3, and caspase-8 (A), or cFLIP and ERK1/2 in the whole cell lysate 
(B). 
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RIPK1 kinase activity is required for TNF/Smac-induced apoptosis and 
TNF/Cx/zVAD- or TNF/Smac/zVAD-induced necroptosis 
While reported to be dispensable for TNF/Cx-induced apoptosis, the kinase 
activity of RIPK1 was implicated in both TNF-induced apoptosis and necroptosis 
under conditions of cIAP depletion and/or caspase inhibition44,160. In agreement 
with these studies, we found that RIPK1 kinase activity in MEFs is not necessary 
for TNF/Cx-induced apoptosis but is required for apoptosis induced by TNF and  
Smac mimetic treatment or necroptosis induced by either TNF/Cx/zVAD or 
TNF/Smac/zVAD stimulation (Figure 6). As expected, RIPK1-deficient MEFs were 
sensitized to TNF/Cx-induced apoptosis81 but resistant to TNF/Cx/zVAD-induced 
necroptosis, given the requirement for RIPK1 kinase activity (Figure 6A). RIPK1 
kinase inhibition by small molecule inhibitors Nec-1 or GSK963A rendered MEFs 
resistant to necroptotic stimuli (Figure 6). Interestingly, RIPK3 kinase inhibitors 
also blocked TNF/Smac/zVAD-induced necroptosis even though necrosome 
formation was not impaired in these cells (Figure 5 and 6B). Thus, necrosome 
formation requires RIPK1 kinase activity but necroptosis execution requires the 
kinase activities of both RIPK1 and RIPK3 in this setting. 
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Figure 6. RIPK1 kinase activity is required for TNF/Smac-induced apoptosis 
and TNF/cycloheximide/zVAD- or TNF/Smac/zVAD-induced necroptosis in 
vitro. SV40-immortalized MEFs generated from WT, Ripk1D138N/D138N, and Ripk1-/- 
mice were treated with TNF (10 ng/ml), zVAD (20 μM), Smac mimetic (1 μM), 
cycloheximide (1 μg/mL), Nec-1 (30 μM), and GSK963A/GSK843A/GSK872B (3 
μM) for 20 hours and cell viability was measured using MTS assay (n = 3 biological 
replicates). Error bars represent SEM.  
 
 
RIPK1 kinase activity mediates necroptosis upon LPS/zVAD treatment in 
primary macrophages 
The TLR3/4-specific adaptor TRIF recruits RIPK1 via the RHIM to mediate 
NF-κB activation; when apoptosis is inhibited, it is thought to recruit RIPK1 and 
RIPK3 to mediate necroptosis256,289. However, TRIF-dependent necroptosis can 
occur in the absence of RIPK1 and may be mediated by the direct recruitment of 
RIPK3 to TRIF and TLR3/4268. To determine whether the kinase activity of RIPK1 
mediates TRIF-dependent necroptosis, primary BMDMs from wild-type (WT) or 
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Ripk1D138N/D138N mice were left untreated or treated with zVAD and/or Nec-1 for 1 
hr prior to stimulation with LPS. LPS and zVAD treatment of WT BMDMs induced 
cell death that was prevented by Nec-1 pretreatment or RIPK3-deficiency (Figure 
7). We found that Ripk1D138N/D138N BMDMs were also protected from LPS–induced 
necroptosis (Figure 7). RIPK1 kinase inactive or Nec-1 pre-treated WT BMDMs 
were similarly resistant to TLR3-induced necroptosis via poly(I:C)/zVAD 
stimulation (data not shown)40. Thus, RIPK1 kinase activity is essential for LPS- 
and poly(I:C)–induced necroptosis in primary BMDMs in vitro40. 
 
Figure 7. RIPK1 kinase activity and RIPK3 mediate LPS/zVAD-induced 
necroptosis in primary macrophages in vitro. Primary BMDMs generated from 
WT, Ripk1D138N/D138N, and Ripk3-/- mice were treated with LPS (20 ng/ml), zVAD 
(20 μM), and Nec-1 (30 μM) for 20 hours and cell viability was measured using 
MTS assay (n = 3 biological replicates). Error bars represent SEM. 
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Discussion 
 Here we demonstrate that RIPK1 kinase activity is required for 
TNF/Smac/zVAD-induced necrosome formation and induction of necroptotic death 
downstream of TNFR1 or TLR3/4 receptors. Additionally, we show that TNF/Smac- 
but not TNF/Cx-induced apoptosis requires RIPK1 kinase activity. By generating 
RIPK1 kinase inactive mice and utilizing their MEFs and BMDMs, we were able to 
use endogenous RIPK1 kinase inactive protein instead of relying on in vitro 
reconstitution or small molecule inhibitors to implicate RIPK1 kinase activity in 
regulating necroptosis43,44.  
RIPK1 and RIPK3 RHIM and kinase activities were both required for 
TNF/Cx/zVAD or TNF/Smac/zVAD-induced necrosome formation and necroptotic 
death in these studies, with a proposed role for auto- and trans-phosphorylation of 
RIPK1 and RIPK3 inducing conformational changes promoting oligomerization 
and amyloid formation43,44. Using RIPK1 kinase inactive MEFs, we demonstrate 
that RIPK1 kinase activity is required for efficient necrosome complex formation 
upon TNF/Smac/zVAD treatment (Figures 4 and 5). In addition to detecting a 
RIPK1/RIPK3/caspase-8 interaction with caspase-8 immunoprecipitation, we 
immunoprecipitated FADD, demonstrating a FADD/RIPK1/caspase-8 complex 
forms in a RIPK1 but not RIPK3 kinase-dependent manner after TNF/Smac/zVAD 
stimulation (data not shown). Due to interference from Ig light and heavy chain, we 
could not clearly detect FADD in the caspase-8 immunoprecipitated complex or 
RIPK3 in the FADD-associated complex. To mitigate this, follow up studies could 
56 
 
 
 
be done with light- or heavy-chain specific secondary antibodies. However, 
contrary to what was reported, we did not detect a constitutive FADD/RIPK3 
interaction in WT MEFs (data not shown)43,181.  
In the absence of RIPK3, a stable TNF/Smac/zVAD-induced caspase-
8/RIPK1 interaction required RIPK1 kinase activity, but these cells were resistant 
to necroptosis due to lack of RIPK3 expression (Figure 5A and data not shown). 
As reported by He et al.44, when present RIPK3 was recruited into this complex II, 
but in a RIPK1 kinase-specific manner. RIPK3 kinase inhibitors seemed to 
potentiate rather than inhibit complex formation, but RIPK3 kinase activity was 
required for induction of necroptosis downstream of complex formation (Figures 
5A and 6B). Similarly, RIPK3 kinase inhibitors did not block a RIPK1/RIPK3 
interaction while RIPK1 kinase activity was required (Figure 4B). In vitro kinase 
assays have demonstrated that RIPK3 can phosphorylate RIPK1, but RIPK1 
phosphorylation of RIPK3 was not detected43,87. However, necrosome formation is 
not affected by RIPK3 kinase inhibition, and RIPK1 may be phosphorylated upon 
TNF/Smac/zVAD-treatment in a RIPK3-independent manner. This is most likely 
auto-phosphorylation, as the slower migrating band is absent when cells are 
treated with RIPK1 kinase inhibitors (Figure 4B). Therefore, a conformational 
change in RIPK1 and activation of its kinase activity may initiate recruitment of 
RIPK3 and mediate their initial RHIM-dependent necrosome interaction. While 
RIPK3 kinase activity appears dispensable for this interaction in MEFs, it is 
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required to activate RIPK3 for downstream recruitment and activation of MLKL to 
induce necroptotic death. 
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Methods 
Immunoblotting 
Mouse embryonic fibroblasts were lysed in RIPA buffer (150 mM NaCl, 50 mM 
Tris-HCl (pH 7.5), 1% NP40, 0.25% deoxycholate, 0.1% SDS, 1 mM EDTA), 
supplemented with protease inhibitors (Roche Applied Science), supplemented 
with sodium orthovanadate (1 mM), phenylmethylsulfonyl fluoride (PMSF, 1 mM), 
and dithiothreitol (DTT, 1 mM). For coimmunoprecipitation, cells were lysed in an 
endogenous lysis buffer (0.5M Tris-HCl pH 7.6, 0.5M NaCl, 0.1M EDTA, 1% Triton 
X-100, 0.5M NaF, and 0.5M sodium pyrophosphate) supplemented with complete 
protease inhibitor cocktail and phosphatase inhibitors (Roche). Total protein was 
run on a 10% SDS-PAGE gel, transferred to a PVDF membrane (Invitrogen) and 
probed with antibodies to caspase-8, RIPK1, RIPK3, cFLIP, and ERK1/2. 
Membranes were developed with Clarity Western ECL Substrate (BioRad). 
 
Cell death assays  
Wild-type, Ripk1D138N/D138N, Ripk1-/-, and Ripk3-/- MEFs were pre-treated 
with 10 μg/ml cycloheximide, 20 μM Zvad (Enzo), 10 μM Smac mimetic 
(ChemiTek), or 30 μm Nec-1 and then treated with 10 ng/ml mTNF (R&D 
Systems). Wild-type, Ripk1D138N/D138N, or Ripk3-/- BMDMs were treated with 20 μM 
zVAD or 30 μM Nec-1 and then with 20 ng/ml LPS. Metabolic activity was assayed 
after 20 hours by addition of MTS reagent (CellTiter 96 AQueous One Solution Cell 
Proliferation Assay, Promega) and measured using a Beckman Coulter DTX880 
plate reader. Absorbance values at 535nm were normalized to control. 
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CHAPTER III 
 
 
RIPK1 kinase inactive mice are resistant to  
TNF- but not LPS-induced shock 
 
 
 
 
*Data in this chapter are unpublished or were originally published in The Journal 
of Immunology. Polykratis A, Hermance N, Zelic M, Roderick J, Kim C, Van TM, 
Lee TH, Chan FKM, Pasparakis M and Kelliher MA. 2014. Cutting edge: RIPK1 
Kinase inactive mice are viable and protected from TNF-induced necroptosis in 
vivo. J Immunol. 193(4):1539-1543. Copyright © [2014] The American Association 
of Immunologists, Inc. 
 
*All experiments and data analysis in Figures 8 to 14 were performed by Matija 
Zelic, with contribution from Nicole Hermance (Figures 8, 10, and 11C and D) and 
Justine Roderick (Figures 8 and 9) 
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Introduction 
As demonstrated in Chapter 2, RIPK1 kinase activity is required for TNF-
induced necrosome formation and TNF- and TLR3/4-mediated necroptosis in vitro. 
RIPK1 and RIPK3 activation results in phosphorylation of MLKL, leading to 
membrane permeabilization and the release of DAMPs289,290. ATP, HMGB1, heat 
shock proteins, and other DAMPs are recognized by innate immune cells and can 
initiate or further amplify proinflammatory cytokine and chemokine production; 
thus, necroptosis is thought to be a more proinflammatory form of cell death 
compared to apoptosis67. RIPK1 has also been suggested to mediate 
cytokine/chemokine transcription or translation in certain settings24,103,277,278. Thus, 
we wanted to test the physiologic role of RIPK1 kinase activity in a mouse model 
where inflammation and necroptosis had been implicated.  
An acute inflammatory model of sterile sepsis used to model lethal systemic 
inflammatory response syndrome (SIRS) is TNF- or TNF/zVAD-induced shock, 
which was reported to depend on necroptosis due to protection in RIPK3-deficient 
mice97. Additionally, caspase inhibition seems to sensitize mice in this shock 
model97,298. However, the role of RIPK1 kinase activity in this model is unclear as 
Nec-1 was found to both sensitize and protect mice from TNF-induced SIRS97–99. 
Another sepsis model involves LPS administration, thus mimicking Gram-negative 
bacterial bloodstream infection, and LPS is known to potently induce TNF 
production in vitro and in vivo299,300. Here we demonstrate that RIPK1 kinase 
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inactive mice are resistant to TNF- and TNF/zVAD-induced shock but littermates 
are not resistant to LPS-induced shock. 
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Results 
RIPK1 D138N mice are resistant to TNF- or TNF/zVAD-induced shock 
TNF administration to mice mimics the histopathological and 
pathophysiologic changes associated with septic shock. We challenged 
Ripk1D138N/D138N mice, as well as WT and Ripk3-/- mice, with 9 μg TNF, a dose 
determined previously in our hands to induce death in 100% of treated WT mice. 
In contrast to WT controls, Ripk1D138N/D138N and Ripk3-/- mice were protected from 
hypothermia, and all of the animals survived the TNF challenge (Figure 8A and B). 
RIPK1 kinase inactive and RIPK3-deficient mice were similarly protected from 
TNF/zVAD-induced shock, which increased the kinetics and penetrance of lethality 
compared to TNF (Figure 8C and D). In these studies, we used age-matched 
males, but the WT and RIPK1 kinase inactive mice were not littermates. To 
determine sensitivity in littermates and whether one kinase inactive RIPK1 allele 
was sufficient for protection, we treated WT, Ripk1D138N/+ and Ripk1D138N/D138N mice 
with a 4-fold higher dose of TNF combined with zVAD. While about half of the 
RIPK1 kinase inactive mice succumbed to this high-dose TNF/zVAD-induced 
shock, they were significantly protected compared to WT mice (Figure 9). 
Interestingly, one kinase inactive allele of RIPK1 was sufficient to mediate 
protection from TNF/zVAD-induced shock, indicating that the relevant cell types in 
this model are sensitive to RIPK1 kinase inactive gene dosage or that the D138N 
mutation has dominant negative activity (Figure 9).  Thus, expression of a kinase-
inactive form of RIPK1 was sufficient to provide protection from TNF-induced 
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hypothermia and mortality in the presence or absence of caspase inhibition and 
we confirmed the protective role of RIPK3 (Figures 8 and 9). Collectively, these 
genetic studies suggest that the mortality induced by TNF in this shock model 
reflects RIPK1- and RIPK3-mediated necroptotic death in vivo. 
 
 
 
 
Figure 8. Ripk1D138N/D138N and RIPK3-deficient mice are protected from TNF- 
or TNF/zVAD-induced shock, a mouse model of systemic inflammatory 
response syndrome. Body temperatures and survival of age- and sex-matched 
wild-type, Ripk1D138N/D138N, and Ripk3-/- mice injected with mTNF (A and B) (p < 
0.0001) or mTNF and zVAD (C and D) (p < 0.0001). 
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A                                                    B 
 
Figure 9. Ripk1D138N/+ littermate mice are protected from high-dose 
TNF/zVAD-induced shock due to gene dosage sensitivity or dominant 
negative kinase activity. Body temperature (A) and survival (B) of wild-type, 
Ripk1D138N/+, and Ripk1D138N/D138N littermates injected with high dose (1.25mg/kg) 
mTNF and zVAD. 
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RIPK1 kinase inactive littermates are susceptible to LPS-induced shock  
 Since RIPK1 kinase inactive mice were resistant to TNF-induced shock and 
LPS administration induces TNF production in vivo, we injected age-matched male 
WT and RIPK1 kinase inactive mice with LPS. Although Ripk1D138N/D138N mice did 
undergo hypothermia in response to a 5 or 10mg/kg dose of LPS, they were 
significantly protected from LPS-induced hypothermia and lethality compared to 
WT controls (Figure 10). However, when we increased the dose of LPS to 
20mg/kg, Ripk1D138N/D138N mice underwent hypothermia and succumbed to LPS-
induced shock at similar rates as WT mice (Figure 11C and D). Thus, RIPK1 kinase 
inactive males may be partially resistant to lower doses of LPS. 
A big problem in mouse models is the heterogeneity of the gut microbiome 
and passenger mutations which are present in various strains of mice, in some 
cases even if mice are back-crossed on to the same strain301,302. Littermate 
controls are therefore crucial to use, especially in mouse models of sepsis. To 
confirm the protection of RIPK1 kinase inactive mice at lower doses of LPS 
administration, we administered 10mg/kg of LPS to WT and Ripk1D138N/D138N 
littermates. However, no differences between WT and RIPK1 kinase inactive mice 
with regards to LPS-induced hypothermia were observed (Figure 11A and B). 
Therefore, unlike the critical role of RIPK1 kinase activity in mediating TNF-induced 
shock (Figures 8 and 9), RIPK1 kinase inactive mice do not seem to ameliorate 
LPS-induced morbidity (Figure 11), as was reported recently by a separate 
group227.  
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Figure 10. Ripk1D138N/D138N non-littermate mice are partially resistant to low 
dose LPS-induced shock. Body temperatures (A and C) and survival (B and D) 
of age- and sex-matched wild-type and Ripk1D138N/D138N mice injected with 5mg/kg 
LPS (A and B) or 10mg/kg LPS (C and D). 
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Figure 11. RIPK1 kinase inactive mice are susceptible to LPS-induced shock 
similar to their WT littermate controls. Body temperatures (A, C) and survival 
(B, D) of littermate (A and B) or age- and sex-matched (C and D) wild-type and 
Ripk1D138N/D138N mice injected with 10mg/kg LPS (A and B) or 20mg/kg LPS (C and 
D). 
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RIPK1 kinase inactive mice exhibit impaired upregulation of LPS-induced 
cytokines and chemokines in vivo 
 Since RIPK1 kinase inactive non-littermate mice were protected from lower 
dose (5mg/kg) LPS administration, we analyzed whether these mice had reduced 
levels of LPS-induced cytokines and chemokines in vivo compared to susceptible 
WT mice. Similar increases in IL-6, CXCL2, CCL2 and CCL5 levels were observed 
in WT and Ripk1D138N/D138N mice at both early (1.5hr) and later (7hr) time points 
(Figure 12). However, levels of TNF, CXCL1, CCL3, CCL4, IL-1β, IL-17α, IFN-γ, 
and GM-CSF were reduced in RIPK1 kinase inactive mice compared to LPS-
treated WT mice at both the early and later time points. These data suggest that 
RIPK1 kinase activity may modulate LPS-induced production of certain cytokines 
and chemokines in vivo. Additionally, the resistance of non-littermate RIPK1 kinase 
inactive mice to lower doses of LPS may in part be mediated by reduced cytokine 
and chemokine levels in vivo.  
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Figure 12. Ripk1D138N/D138N mice are impaired in their ability to upregulate an 
LPS-driven proinflammatory cytokine and chemokine signature in vivo. 
Plasma cytokine and chemokine levels in WT and Ripk1D138N/D138N mice 1.5 and 7 
hours after intraperitoneal LPS (5mg/kg) administration (n = 4-6) Error bars 
represent SEM.  
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RIPK1 kinase activity partially impairs LPS/zVAD-induced cytokine and 
chemokine production in vitro 
To test whether RIPK1 kinase is required for transcriptional activation of 
inflammatory cytokines/chemokines, we isolated primary BMDMs from WT and 
Ripk1D138N/D138N mice and stimulated them in vitro with LPS or LPS/zVAD for 6 
hours. LPS- or LPS/zVAD-induced Il6 and Ccl5 levels were normally increased in 
Ripk1D138N/D138N BMDMs, consistent with their upregulation in vivo in 
Ripk1D138N/D138N mice (Figures 12 and 13). Interestingly, we found that the kinase 
activity of RIPK1 was required for the induction of Tnf and Csf2 (GM-CSF), but not 
Cxcl1 and Il-1β in response to LPS/zVAD treatment (Figure 13). However, in vivo 
the secretion of these 4 cytokines/chemokines was reduced in LPS-treated RIPK1 
kinase inactive mice, suggesting that perhaps RIPK1 affects CXCL1 and IL-1β 
translation or processing, but not transcriptional upregulation. Meanwhile, LPS-
induced responses were similar between WT and RIPK1 kinase inactive BMDMs 
for the cytokines/chemokines analyzed. Thus, RIPK1 kinase activity may 
contribute to LPS/zVAD-induced TNF and GM-CSF transcription in primary 
BMDMs in vitro, and may be responsible for the reduction in cytokine and 
chemokine levels during LPS-induced shock in vivo. 
We did not detect significant differences in LPS- or LPS/zVAD-induced TNF 
or IL-6 secretion at 6 or 22 hours between WT and Ripk1D138N/D138N BMDMs (Figure 
14A). Even though TNF secretion was consistently decreased in LPS- or 
LPS/zVAD-treated RIPK1 kinase inactive BMDMs, the difference was not 
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significant (Figure 14A) while LPS/zVAD-induced Tnf upregulation was 
significantly reduced in RIPK1 kinase inactive macrophages (Figure 13). Similar to 
LPS-induced Il-1β expression, IL-1β secretion levels were similar in WT and RIPK1 
kinase inactive BMDMs primed with LPS and stimulated with polydA:dT, silica, or 
ATP (Figure 14B). Thus, RIPK1 kinase activity is dispensable for canonical NLRP3 
inflammasome activation.  
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Figure 13. RIPK1 kinase activity is required for LPS/zVAD-induced Tnf and 
Csf2 expression in primary macrophages in vitro. Quantitative RT-PCR 
analysis of TNFα, Il6, Cxcl1, Ccl5, Csf2, and Il1b expression in WT and 
Ripk1D138N/D138N primary macrophages treated with LPS or LPS/zVAD for 6 hours 
(n = 3 mice). Error bars represent SEM. 
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Figure 14. Ripk1D138N/D138N primary macrophages do not contribute to LPS 
or LPS/zVAD-induced TNF, IL-6, or IL-1β up-regulation in vitro. (A) Secretion 
of TNF and IL-6 in WT and Ripk1D138N/D138N primary macrophages 6 and 22 hours 
after addition of LPS or LPS/zVAD (n = 3 mice). (B) Secretion of IL-1β in WT and 
Ripk1D138N/D138N primary macrophages 6 hours after addition of polydA:dT or 
silica, or 45 minutes after ATP addition. Macrophages were primed for 3 hours 
with LPS (n = 3 mice). 
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Discussion 
 Here we demonstrate that RIPK1 kinase activity is required for TNF and 
TNF/zVAD-induced shock in mice, but seems dispensable for LPS-induced shock, 
at least in littermates. Additionally, we show that non-littermate RIPK1 kinase 
inactive mice that are partially resistant to LPS-induced shock fail to upregulate 
some, but not all LPS-induced cytokines and chemokines examined. In BMDMs in 
vitro, however, we find RIPK1 kinase inactive cells impair only Tnf and Csf2 
transcriptional upregulation in response to LPS/zVAD but not LPS treatment. 
 We demonstrate the requirement of both RIPK1 kinase activity and RIPK3 
in a mouse model of TNF- or TNF/zVAD-induced shock. Caspase inhibition 
sensitized mice to TNF-induced shock, as reported previously, suggesting RIPK1 
and RIPK3-driven necroptosis plays an integral part in inducing the shock and 
lethality97,298. Though we did not use littermates in Figure 8, we used age-matched 
males that were co-housed for a few weeks prior to treatment when possible. 
Importantly, when we treated littermates with zVAD and a 4-fold higher dose of 
TNF, we still saw significant protection in RIPK1 kinase inactive mice compared to 
WT controls (Figure 9). Surprisingly, heterozygous RIPK1 kinase inactive mice 
(Ripk1D138N/+) were as resistant as their homozygous kinase inactive littermates, 
demonstrating that the D138N mutation may act as a dominant negative in cell 
types crucial in mediating TNF-induced signaling and lethality in this shock model. 
 The importance of littermate controls was exemplified by our LPS studies. 
We found that RIPK1 kinase inactive mice littermates were sensitized to LPS-
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induced hypothermia similarly to WT mice when treated with 10mg/kg LPS, in 
agreement with a recent report227. While this dose did not induce lethality, non-
littermate RIPK1 kinase inactive were similarly sensitive as WT mice to lethality 
induced by 20mg/kg LPS administration (Figure 11). Although RIPK1 kinase 
inactive mice are resistant to TNF-induced shock and LPS administration induces 
TNF production, RIPK1 kinase inactive littermates are susceptible to LPS-induced 
shock. However, our initial experiments performed in non-littermate, age-matched 
males indicated that RIPK1 kinase inactive mice were partially resistant to LPS 
doses of 5mg/kg and 10mg/kg compared to WT mice, and these doses induced 
lethality in more than 50% of WT controls (Figure 10). Thus, we observed 
differences in LPS-induced shock and dose sensitization in both WT and RIPK1 
kinase inactive mice once we repeated the experiment in littermates. Part of the 
dose-dependent sensitization difference could also be due to varying potency in 
different LPS batch preparations. 
 In non-littermates treated with 5mg/kg LPS we observed a reduction in 
various LPS-induced cytokines and chemokines in RIPK1 kinase inactive mice 
(Figure 12), consistent with a recent study showing RIPK1 kinase activity promotes 
LPS-induced inflammatory responses277. Consistent reductions in LPS-treated 
Ripk1D138N/D138N mice were observed for TNF, GM-CSF, and IL-1β levels (Figure 
12), indicating that RIPK1 kinase activity may regulate their transcription or 
translation. Indeed, the relative expression of Tnf and Csf2 was reduced in 
LPS/zVAD- but not LPS-treated RIPK1 kinase inactive BMDMs (Figure 13), while 
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TNF secretion was not significantly reduced in LPS- or LPS/zVAD-treated BMDMs 
(Figure 14A). The discrepancy between LPS/zVAD-induced TNF transcriptional 
and translational responses in vitro is unclear but may reflect differences in kinetics 
and/or a partial requirement for RIPK1 kinase activity. Meanwhile, the induction of 
Il-1β expression was unaffected by lack of RIPK1 kinase activity (Figure 13) and 
canonical NLRP3 inflammasome activation and IL-1β secretion was not impaired 
in RIPK1 kinase inactive BMDMs (Figure 14B), although LPS-induced IL-1β levels 
in vivo were reduced in Ripk1D138N/D138N mice (Figure 12). Perhaps RIPK1 
regulation in other cell types contributes to differences observed in mice. 
Alternatively, the canonical NLRP3 inflammasome activators we used in vitro may 
not reflect the mechanism of IL-1β processing and secretion in response to lethal 
LPS-induced shock.  
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Methods 
Mice  
Ripk1D138N/D138N knock-in mice were generated by mutating the conserved 
aspartate (D) at position 138 to asparagine (D138N). The Ripk1D138N construct was 
introduced into Bruce 4 embryonic stem cells derived from C57BL/6 mice. Mice 
were maintained at the specific pathogen–free animal facilities of the University of 
Massachusetts Medical School and the Institute for Genetics at the University of 
Cologne. All animal procedures were conducted in accordance with national and 
institutional guidelines. Sex- and age-matched mice were used in all experiments. 
 
TNF- and LPS-induced shock experiments 
Age- and sex-matched wild-type, Ripk1D138N/D138N and Ripk3-/- mice were 
injected intravenously with 9 μg mTNF only or with zVAD-fmk (16.7 mg/kg). LPS 
was injected intraperitoneally at varying doses (5, 10, or 20mg/kg). Body 
temperature and survival were monitored. 
 
Cytokine Analysis 
Plasma cytokines were measured using a 12-plex protein/peptide multiplex 
analysis (Luminex Technology) conducted by the National Mouse Metabolic 
Phenotyping Center at the University of Massachusetts Medical School. Cytokines 
and chemokines that were below the limit of detection were assigned a value of 
zero. Blood was collected via cardiac puncture in a heparinized needle and spun 
down to isolate plasma. The samples were stored at -80°C until analysis. IL-6 
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(eBioscience), TNF, and IL-1β secretion by cultured primary cells was determined 
by ELISA.  
 
Gene expression Analysis  
Primary BMDMs were treated with LPS (10ng/mL) and 50 μM zVAD (Enzo) 
for 6 hours. Total cellular RNA was isolated using an RNeasy Mini Kit (QIAGEN). 
cDNA was prepared using the Superscript First-Strand Synthesis System 
(Invitrogen). Quantitative real-time PCR was performed using Power SYBR Green 
PCR Master Mix (Applied Biosystems) and run on the AB7300 Detection System 
(Applied Biosystems). Relative gene expression was normalized to Actin and 
determined using the CT method, with the following primer sequences: 
Gene symbol Direction Primer sequence (5' to 3') 
Actin For CGAGGCCCAGAGCAAGAGAG 
Rev CGGTTGGCCTTAGGGTTCAG 
Tnf For CAGTTCTATGGCCCAGACCCT 
Rev CGGACTCCGCAAAGTCTAAG 
Il6 For AACGATGATGCACTTGCAGA 
Rev GAGCATTGGAAATTGGGGTA 
Ccl5 For GCCCACGTCAAGGAGTATTTCTA 
Rev ACACACTTGGCGGTTCCTTC 
Cxcl1 For CTGGGATTCACCTCAAGAACATC 
Rev CAGGGTCAAGGCAAGCCTC 
Csf2 (GM-
CSF) 
For GGCCTTGGAAGCATGTAGAGG 
Rev GGAGAACTCGTTAGAGACGACTT 
Il-1β For GCCCATCCTCTGTGACTCAT 
Rev AGGCCACAGGTATTTTGTCG 
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CHAPTER IV 
 
 
RIP kinase 1-dependent endothelial necroptosis 
underlies lethal TNF/zVAD-induced  
systemic inflammatory response syndrome  
 
 
 
 
*Data in this chapter are part of a manuscript in revision at JCI: Zelic M, Roderick 
JE, O’Donnell JA, Lehman J, Lim SE, Janardhan HP, Trivedi CM, Pasparakis M, 
and Kelliher MA. RIP kinase 1-dependent endothelial necroptosis underlies 
systemic inflammatory response syndrome. J. Clin. Inv.  
 
 
*All experiments and data analysis shown in Figures 15 to 28 were performed by 
Matija Zelic, with contribution from Jo O’Donnell (Figures 17, 19, and 20), Justine 
Roderick (Figures 17, 18, 20, 22, and 27), Jesse Lehman (Figures 17 and 20), 
Harish Janardhan (Figure 24), and Nicole Hermance (Figure 23) 
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Introduction 
The recent generation of kinase inactive Ripk1D138N/D138N and Ripk1K45A/K45A 
mice has elucidated the role of RIPK1 kinase activity in necroptosis and in mouse 
models of acute and chronic inflammatory disease24,40,41. As demonstrated in 
Chapter 3, and similar to Ripk3-/- mice, RIPK1 kinase inactive Ripk1D138N/D138N mice 
are protected from TNF- or TNF/zVAD-induced acute shock, a model of SIRS40,97 
(Figures 8 and 9). SIRS can be triggered by sterile inflammation including injury 
from burns, trauma, or acute pancreatitis, and upon infection can lead to sepsis 
and septic shock303,304. It has long been hypothesized that the “cytokine storm” 
drives shock, with excess production of proinflammatory cytokines such as TNFα 
and IL-1β triggering vascular dysfunction and organ injury303. However, attempts 
over the last couple of decades to block TNF or IL-1R signaling in septic patients 
have largely failed to provide a survival benefit305–307.  
Although necroptosis has recently been implicated in the pathogenesis of 
TNF-induced shock and SIRS24,40,41,97, the precise cell types undergoing 
necroptosis and the relative contribution of the “cytokine storm” remain unclear. 
Here, we demonstrate that proinflammatory cytokine/chemokine levels do not 
correlate with hypothermia or survival in this mouse SIRS model, and that non-
hematopoietic RIPK1 kinase inactive cells mediate resistance to TNF- or 
TNF/zVAD-induced shock. Additionally, we show that WT liver endothelial cells 
undergo MLKL activation and cell death, indicating that endothelial cell necroptosis 
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contributes to increased vascular permeability, coagulation, and organ injury 
observed in TNF/zVAD-treated WT but not RIPK1 kinase inactive mice. 
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Results 
RIPK1 kinase activity regulates cytokine/chemokine production and 
neutrophil infiltration in response to TNF and TNF/zVAD 
TNF shock mimics systemic SIRS, which is thought to be driven by the 
proinflammatory “cytokine storm”. To assess the role of RIPK1 kinase activity in 
the “cytokine storm”, we analyzed proinflammatory cytokine and chemokine levels 
in the plasma of TNF- or TNF/zVAD-treated mice. Similar increases in CXCL1, 
CCL3, CCL4, CCL5, and IL-6 levels were observed in Ripk1D138N/D138N and WT 
mice at early time points after TNF administration (Figure 15A). However, CXCL2 
levels were consistently decreased in Ripk1D138N/D138N mice, suggesting that RIPK1 
kinase activity may be required for optimal TNF-induced CXCL2 production in vivo 
(Figure 15A). Cytokine and chemokine levels were consistently reduced at 7 hours 
in RIPK1 kinase inactive mice compared to TNF-treated WT mice (Figure 15A). 
The addition of the pan-caspase inhibitor zVAD sensitizes WT mice to TNF shock 
and decreases time to lethality40,97,298. To ascertain whether TNF/zVAD 
sensitization correlates with increased proinflammatory cytokine levels, we 
compared TNF- and TNF/zVAD-induced plasma cytokine/chemokine levels at 2 
hours. Interestingly, WT mice treated with TNF/zVAD exhibited significantly 
elevated plasma cytokine and chemokine levels compared to treatment with TNF 
alone, especially for CXCL2, CCL3, CCL4, and IL-6 (Figure 15B). IL-1β and IL-17α 
levels, which are found increased in septic patients308,309, were elevated 
systemically in WT mice treated with TNF/zVAD but not TNF (Figure 15B). While 
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the addition of zVAD amplified cytokine and chemokine levels in WT mice, 
Ripk1D138N/D138N mice exhibited significantly lower plasma levels of proinflammatory 
cytokines and chemokines (Figure 15B). Overall, these results suggest that the 
plasma proinflammatory cytokine/chemokine levels correlate with the kinetics of 
hypothermia and lethal shock. Furthermore, these data suggest that TNF/zVAD 
sensitizes mice to necroptotic death in vivo, which is postulated to be 
proinflammatory due to DAMP release67. 
Recently, the kinase activity of RIPK1 has been implicated in the 
transcriptional regulation of certain cytokines and chemokines in response to 
TNF/zVAD or LPS/zVAD treatment24,103,277,278. To test whether RIPK1 kinase is 
required for transcriptional activation of inflammatory cytokines/chemokines, we 
isolated primary BMDMs from WT and Ripk1D138N/D138N mice and stimulated them 
in vitro with TNF or TNF/zVAD. We found that the kinase activity of RIPK1 was 
required for the induction and production of CXCL1, CXCL2, and IL-6, but not 
CCL5, in response to TNF/zVAD (Figure 16, A and B). Interestingly, 
Ripk1D138N/D138N BMDMs also exhibited reduced CXCL2 expression and secretion 
when treated with TNF alone, indicating that RIPK1 kinase activity is necessary for 
optimal TNF-induced Cxcl2 upregulation in vitro (Figure 16, A and B). Thus, RIPK1 
kinase activity contributes to TNF and TNF/zVAD-induced cytokine and chemokine 
transcription in primary BMDMs in vitro, and may be responsible for reduced 
cytokine and chemokine levels during TNF shock in vivo. 
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Figure 15. Ripk1D138N/D138N mice exhibit impaired cytokine and chemokine 
production in response to TNF and TNF/zVAD administration in vivo. (A) 
Plasma cytokine and chemokine levels in WT and Ripk1D138N/D138N mice 2 and 7 
hours after intravenous TNF administration (n = 8-9) or (B) 2 hours after 
intravenous TNF or TNF/zVAD administration (n = 6-9). TNF-induced levels are 
repeated from (A). Error bars represent mean ± SEM. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001, by 2-tailed Student’s t test. 
 
 
 
85 
 
 
 
 
Figure 16. RIPK1 kinase activity contributes to TNF- and TNF/zVAD-induced 
CXCL1 and CXCL2 chemokine and IL-6 cytokine production in vitro. (A) 
Quantitative RT-PCR analysis of Cxcl1, Cxcl2, Il6, and Ccl5 expression in WT and 
Ripk1D138N/D138N primary macrophages treated with TNF or TNF/zVAD for 2 or 6 
hours (n = 3 mice). Graphs show relative mRNA expression normalized to Actin. 
(B) Secretion of CXCL1, CXCL2, IL-6 and CCL5 as determined by ELISA in WT 
and Ripk1D138N/D138N primary macrophages 6 or 22 hours after addition of TNF or 
TNF/zVAD (n = 3 mice).  
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To determine whether reductions in cytokine/chemokine levels in RIPK1 
kinase inactive mice result in decreased inflammatory cell mobilization and 
infiltration, we analyzed peripheral blood, bone marrow, spleen, lung, and liver for 
evidence of inflammatory macrophage and neutrophil recruitment in response to 
TNF or TNF/zVAD administration. Systemic TNF administration mobilized 
inflammatory macrophages and neutrophils from the spleens and bone marrow of 
WT and Ripk1D138N/D138N mice (Figure 17, A and B). However, more neutrophils 
were detected in Ripk1D138N/D138N spleen and bone marrow compared to TNF-
treated WT mice (Figure 17, A and B). TNF-induced inflammatory monocyte 
recruitment to the blood and similar numbers of inflammatory 
monocytes/macrophages were detected in the lungs and liver of TNF-treated WT 
and Ripk1D138N/D138N mice (Figure 17, C-E). Consistent with reduced levels of 
neutrophil chemoattractant CXCL2 (Figure 15A), TNF-treated Ripk1D138N/D138N 
mice exhibited decreased neutrophil mobilization from the bone marrow and 
spleen into the blood. However, inflammatory cell infiltration in lung and liver was 
similar for WT and Ripk1D138N/D138N mice treated with TNF (Figure 17, C-E). 
Although TNF/zVAD administration to WT mice results in a more robust 
cytokine/chemokine response (Figure 15B), this did not result in significant 
increases in inflammatory cell mobilization into blood, lung or liver compared to 
treatment with TNF only (Figure 17, C-E). Although TNF/zVAD treatment 
significantly increased neutrophil numbers in the spleen and bone marrow, 
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Ripk1D138N/D138N mice exhibited reduced neutrophil infiltration into lung and liver 
(Figure 17). Activated neutrophils can release proteases and ROS, thereby 
damaging organs and further increasing cytokine production310. Thus, the reduced 
cytokine/chemokine levels and neutrophil infiltration observed in TNF and 
TNF/zVAD-treated Ripk1D138N/D138N mice may be responsible for the protection.  
 
Figure 17. Impaired recruitment of Ripk1D138N/D138N neutrophils to the lung and 
liver in response to TNF or TNF/zVAD administration. (A, B) Splenocytes and 
bone marrow cells were stained with antibodies, analyzed by flow cytometry and 
the number of inflammatory monocytes/macrophages or neutrophils determined. 
The number of cells for WT and Ripk1D138N/D138N mice left untreated (Unt.) or 
treated with TNF (7h) or TNF/zVAD (4h) (n = 3-5) is shown. (C) The number of 
inflammatory monocytes or neutrophils in peripheral blood of WT and 
Ripk1D138N/D138N mice is shown (n = 3-5). (D, E) The number of inflammatory 
macrophages or neutrophils in lung and liver of WT and Ripk1D138N/D138N mice left 
untreated (Unt.) or treated with TNF (7h) or TNF/zVAD (4h) (n = 4-5) is shown. 
*p<.05, **p<0.01, ***p<0.001, ****p<0.0001, by 2-tailed Student’s t test. 
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RIPK1 kinase activity in a non-hematopoietic lineage is responsible for TNF- 
and TNF/zVAD-induced lethality 
These data suggest that inflammatory cells mediate organ damage and 
predict that RIPK1 kinase inactive hematopoietic cells provide protection in this 
SIRS model. To test this, we generated reciprocal bone marrow chimeras by 
transplanting WT or Ripk1D138N/D138N bone marrow cells into lethally irradiated 
syngeneic recipients (Figure 18A). Two months post-reconstitution, RIPK1 kinase 
inactive donor-derived cells repopulated irradiated recipients as effectively as WT 
cells (Figure 19, A-C), indicating that RIPK1 kinase activity does not contribute to 
the cell-intrinsic survival function of RIPK1 in hematopoietic cells180,311. We next 
tested the TNF response and as expected, WT controls developed hypothermia in 
response to TNF (Figure 18B) or TNF/zVAD (Figure 18D) administration and 
succumbed to shock. Unexpectedly, Ripk1D138N/D138N  WT mice succumbed with 
similar kinetics as WT  WT controls in response to TNF (Figure 18C) or 
TNF/zVAD (Figure 18E) administration. Interestingly, WT  Ripk1D138N/D138N mice 
were completely protected from TNF- or TNF/zVAD-induced shock (Figure 18, B-
E). These data reveal that a non-hematopoietic Ripk1D138N/D138N lineage(s) 
mediates protection from TNF- and TNF/zVAD-induced shock. 
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Figure 18. Non-hematopoietic RIPK1 kinase inactive cells mediate protection 
against lethal TNF- and TNF/zVAD-induced shock. (A) Experimental design. 
Body temperature (B, D) and Kaplan-Meier survival curves (C, E) after TNF- (B, 
C) or TNF/zVAD-induced shock (D, E) are depicted for lethally irradiated WT and 
Ripk1D138N/D138N mice reconstituted with WT or Ripk1D138N/D138N bone marrow cells. 
Error bars represent mean ± SEM. *p<.05, ***p<0.001, ****p<0.0001, by Mantel-
Cox test. 
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Figure 19. Kinase inactive RIPK1 bone marrow cells effectively repopulate 
lethally irradiated hosts. Graphs depicting the percentage of donor-derived 
myeloid and lymphoid lineages in the spleen (A), bone marrow (B), and blood (C) 
at 8 weeks post-transplantation (n = 4-8 mice). Error bars represent mean ± SEM. 
IMs: Inflammatory Macrophages, DCs: Dendritic Cells. 
 
Cytokine levels and neutrophil infiltration do not correlate with survival 
To further examine any contribution of the “cytokine storm”, we measured 
proinflammatory cytokine and chemokine levels in the plasma of TNF-treated 
reconstituted mice. Comparable to what we observed in non-reconstituted mice, 
TNF treatment similarly upregulated cytokine and chemokine levels at 2 hours in 
all the bone marrow chimeras, notably revealing that RIPK1 kinase activity does 
not appear to regulate cytokine transcription during TNF shock (Figure 20A). While 
cytokine/chemokine levels were further elevated in WT controls 7 hours after TNF 
administration, unexpectedly both sensitive Ripk1D138N/D138N  WT and resistant 
WT  Ripk1D138N/D138N chimeras exhibited significant decreases in 
cytokine/chemokine levels (Figure 20A), demonstrating that cytokine/chemokine 
levels do not predict survival. These data also suggest that RIPK1 kinase inactive 
hosts lack a secondary trigger, potentially provided by the necroptosis of 
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nonhematopoietic cells, which may amplify proinflammatory signaling by feeding 
back on necroptosis-competent WT hematopoietic cells. Additionally, the data 
suggest that in sensitive Ripk1D138N/D138N  WT mice, DAMPs released from 
necroptotic WT non-hematopoietic cells fail to amplify cytokine/chemokine levels 
to levels observed in WT  WT mice, potentially because Ripk1D138N/D138N 
hematopoietic cells do not undergo necroptosis (Figure 20A). Furthermore, we 
found that TNF/zVAD treatment resulted in greater increases in 
cytokine/chemokine levels at 2 hours in both sensitive Ripk1D138N/D138N  WT and 
resistant WT  Ripk1D138N/D138N chimeras compared to treatment with TNF only 
(Figure 21), suggesting that necroptosis amplifies proinflammatory 
cytokine/chemokine production. Additionally, maximal cytokine/chemokine 
production requires RIPK1 kinase activity in both hematopoietic and non-
hematopoietic lineages, whereas a lack of RIPK1 kinase activity in a non-
hematopoietic lineage provides protection. 
We observed similar mobilization and infiltration of inflammatory 
monocytes/macrophages and neutrophils into the blood, lung and liver of all TNF-
treated reconstituted groups (Figure 20, B-D). In fact, more inflammatory 
macrophages and neutrophils infiltrated the lung and liver, respectively, of 
protected WT  Ripk1D138N/D138N chimeras compared to sensitive Ripk1D138N/D138N 
 WT mice. This finding suggests that a lack of RIPK1 kinase activity in either 
hematopoietic or non-hematopoietic cells does not abrogate TNF-induced 
inflammatory cell recruitment. 
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Figure 20. Proinflammatory cytokines and inflammatory cell recruitment do 
not correlate with survival in a TNF-induced model of shock. (A) Plasma 
cytokine and chemokine levels in reconstituted mice 2 and 7 hours after 
intravenous TNF administration (n = 4-7). Graphs depicting the number of 
inflammatory monocytes/macrophages and neutrophils in the blood (B), lungs (C), 
or liver (D) of lethally irradiated WT and Ripk1D138N/D138N mice reconstituted with 
WT or Ripk1D138N/D138N bone marrow cells as measured by flow cytometry 8 hours 
after systemic TNF administration (n = 4-5).  Error bars represent mean ± SEM. 
*p<0.05, **p<0.01, ***p<0.001, by two-way (A) or one-way ANOVA with post hoc 
Tukey test (B-D). 
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Figure 21. TNF/zVAD-treated RIPK1 kinase inactive hosts exhibit reduced 
cytokine and chemokine production compared to WT hosts reconstituted 
with RIPK1 kinase inactive hematopoietic cells. Plasma cytokine and 
chemokine levels in reconstituted mice 2 hours after intravenous TNF or 
TNF/zVAD administration (n = 3-7). TNF-induced levels are repeated from Figure 
4A. Error bars represent mean ± SEM. *p<0.05, **p<0.01, by 2-tailed Student’s t 
test. 
 
 
TNF-induced increases in intestinal permeability require RIPK1 kinase 
activity  
Since RIPK1 kinase inactive hematopoietic cells proved not to be the critical 
lineage mediating protection from TNF shock (Figure 18), we examined other 
lineages affected by TNF administration. TNFR1 expression levels in intestinal 
epithelial cells (IECs) have been shown to correlate with TNF-induced increases 
in intestinal permeability and overall lethality in mice312,313. To assess intestinal 
permeability, we measured the plasma fluorescence levels of orally gavaged FITC-
conjugated dextran beads following TNF administration. WT mice exhibited a 
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significant increase in intestinal permeability but no increase in intestinal 
permeability was observed in Ripk1D138N/D138N mice upon TNF administration 
(Figure 22A). Although Ripk1D138N/D138N mice were protected from TNF-induced 
lethality, cleaved caspase-3 staining revealed similar numbers of apoptotic 
colonocytes in WT and RIPK1 kinase inactive mice (Figure 23B). Interestingly, WT 
mice had slightly elevated numbers of cleaved caspase-3 positive cells in the 
ileum, suggesting that ileal IECs may undergo RIPK1 kinase-mediated apoptosis 
in response to TNF (Figure 23A). Importantly, TNF/zVAD administration similarly 
suppressed ileal and colonic IEC apoptosis in WT and Ripk1D138N/D138N mice, 
suggesting that intestinal apoptosis is not responsible for the lethality observed in 
WT mice (Figure 23, A and B). Since intestinal leakage could disseminate the gut 
microflora systemically, activate TLR signaling, and amplify inflammatory cytokine 
production313, we quantified bacterial growth in spleen and liver lysates from 
untreated and TNF-treated WT and Ripk1D138N/D138N mice (Figure 22B). Although 
TNF augmented intestinal permeability, we could not detect an increase in 
bacterial colonies from spleen and liver lysates when WT mice were treated with 
TNF (Figure 22B), indicating that changes in intestinal permeability were not 
sufficient to induce systemic bacteremia in this intravenous TNF shock model.  
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Figure 22. Non-hematopoietic RIPK1 kinase inactive cells mediate protection 
against TNF-induced intestinal and vascular hyperpermeability and 
coagulation. (A) FITC-labeled dextran beads were administered to WT and 
Ripk1D138N/D138N mice by oral gavage 2 hours after TNF injection. Blood was 
isolated by cardiac puncture and the levels of FITC-dextran in plasma measured 
by fluorometry (n = 4-7). (B) Bacterial growth in spleen and liver lysates isolated 
from untreated WT and Ripk1D138N/D138N mice or 10 hours after injection with 15 μg 
TNF (n = 3-6). (C) WT and Ripk1D138N/D138N mice were injected with TNF and Evans 
Blue dye, organs were collected and the amount of dye extracted from the lung 
and liver was measured by spectrophotometry (n = 7-8). (D) Tissue factor levels 
were determined by ELISA in the plasma of TNF- or TNF/zVAD-treated WT and 
Ripk1D138N/D138N mice (n = 3-7). (E) WT and Ripk1D138N/D138N reconstituted mice 
were injected with TNF and Evans Blue dye, and the amount of dye extracted from 
the lung and liver was measured by spectrophotometry (n = 6-7). (F) Tissue factor 
levels in the plasma of reconstituted WT and Ripk1D138N/D138N mice treated with 
TNF (n = 3-5). Error bars represent mean ± SEM. *p<0.05, **p<0.01, by 2-tailed 
Student’s t test (A-D) or one-way ANOVA with post hoc Tukey test (E-F). 
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Figure 23. Kinase inactive RIPK1 mice are modestly protected from TNF-
induced ileal but not colonic intestinal epithelial apoptosis. Quantification of 
cleaved caspase-3 positive cells per 40x field in the ileum (A) and colon (B) of WT 
and Ripk1D138N/D138N mice 2 hours after TNF or TNF-zVAD administration (n = 3). 
Error bars represent mean ± SEM. *p<0.05, **p<0.01, by 2-tailed Student’s t test. 
 
 
RIPK1 kinase activity is required for TNF-induced increases in vascular 
permeability and clotting 
In addition to increasing intestinal epithelial permeability, TNF stimulates 
vascular permeability and endothelial activation by upregulating the expression of 
adhesion molecules and by stimulating cytokine and chemokine production314,315. 
To quantitatively assess TNF-induced vascular permeability changes we 
measured the extravasation of Evans Blue dye. TNF administration induced 
significant increases in vascular permeability, resulting in Evans Blue dye leakage 
into the lung and liver of WT mice, while Ripk1D138N/D138N mice exhibited no 
detectable increase in vascular permeability (Figure 22C). Additionally, WT mice 
exhibited activation of the extrinsic coagulation cascade as evidenced by 
significant increases in plasma tissue factor levels following TNF or TNF/zVAD 
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administration (Figure 22D). To determine whether RIPK1 kinase activity in 
endothelial cells was responsible for the increased vascular permeability, we 
examined these vascular parameters in chimeric mice. WT  WT and 
Ripk1D138N/D138N  WT chimeras, which remain sensitive to TNF-induced shock, 
displayed increased vascular permeability in their lungs and liver (Figure 22E) and 
exhibited elevated tissue factor levels during TNF-induced shock (Figure 22F). 
Notably, WT  Ripk1D138N/D138N mice, which were protected from TNF-induced 
shock, showed no significant increase in TNF-induced lung or liver permeability 
and maintained basal levels of plasma tissue factor in response to TNF (Figure 22, 
E and F). These data suggest that RIPK1 kinase activity in endothelial cells is 
responsible for TNF-induced increases in vascular permeability and coagulation.  
Consistent with these data, histological examination of the livers in TNF- and 
TNF/zVAD-treated WT mice revealed significant increases in blood vessel clotting 
compared to untreated controls (Figure 24, A and B). We observed neutrophil and 
erythrocyte adhesion to the endothelium and leakage of erythrocytes and 
leukocytes into the extravascular space due to increased vascular permeability 
(Figure 24A). Although we observed some evidence of neutrophil and erythrocyte 
adhesion and clotting in the TNF- and TNF/zVAD-treated Ripk1D138N/D138N liver 
sections, there was a significant reduction in clotting in the liver blood vessels 
(Figure 24, A and B). To quantify clotting function, we performed a prothrombin 
time test. Blood isolated from TNF-treated WT mice took significantly longer to clot 
compared to RIPK1 kinase inactive mice (Figure 24C), suggesting that coagulation 
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factors were consumed in TNF-treated WT mice due to activation of the extrinsic 
clotting cascade. These results demonstrate that lack of RIPK1 kinase activity in 
endothelial cells protects from TNF- and TNF/zVAD-induced increases in vascular 
permeability and coagulation. 
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Figure 24. Kinase inactive RIPK1 mice are protected from TNF- or TNF/zVAD-
induced breaks in the liver endothelium and coagulation, and liver 
endothelial cell necroptosis induced by TNF/zVAD treatment. (A) 
Representative images of Hematoxylin and Eosin stained liver sections from WT 
or Ripk1D138N/D138N mice left untreated or injected intravenously with TNF or 
TNF/zVAD (n = 3-4 mice). Scale bar: 100 μm (10x), 50 μm (40x). (B) Quantification 
of clotting observed in liver blood vessels of mice shown in (A). (C) Citrated plasma 
was isolated from WT and Ripk1D138N/D138N mice 7 hours after TNF administration 
and clot formation time was measured by the prothrombin time test (n = 4 mice). 
(D) Representative images of endomucin stained liver sections from untreated, or 
TNF- or TNF/zVAD-treated WT and Ripk1D138N/D138N mice (n = 3-4 mice). Scale 
bar: 50 μm (40x). (E) WT and Ripk1D138N/D138N liver endothelial cells were isolated 
from untreated or TNF/zVAD-treated mice. A representative western blot showing 
protein lysates probed with antibodies to phospho-MLKL, MLKL and ERK1/2 is 
depicted (Lysates were generated and analyzed from 14 WT and 8 Ripk1D138N/D138N 
TNF/zVAD-treated mice). Error bars represent mean ± SEM. **p<0.01, by 2-tailed 
Student’s t test. 
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TNF-induced adhesion molecule expression does not require RIPK1 kinase 
activity 
We hypothesized that RIPK1 kinase activity may regulate vascular 
permeability by directly mediating endothelial cell activation. To test this possibility, 
we isolated primary endothelial cells from the lungs of WT and Ripk1D138N/D138N 
mice and measured ICAM-1, VCAM-1, E-selectin and P-selectin mRNA levels via 
real-time quantitative PCR. We detected no significant differences in TNF-induced 
ICAM-1, VCAM-1, E-selectin and P-selectin upregulation in WT and 
Ripk1D138N/D138N primary lung endothelial cells, indicating that RIPK1 kinase activity 
is not required for TNF-induced endothelial activation in vitro (Figure 25A). 
Endothelial cells upregulate neutrophil chemokines CXCL1 and CXCL2 in 
response to TNF stimulation315. Thus, we examined CXCL1 and CXCL2 
expression and secretion but failed to detect any significant differences in 
endothelial chemokine production between WT and RIPK1 kinase inactive 
endothelial cells (Figure 25, A and B). We then assessed whether RIPK1 kinase 
activity influenced endothelial cell activation in vivo. After TNF or TNF/zVAD 
administration, we isolated RNA from WT and Ripk1D138N/D138N lung or liver and 
examined adhesion molecule and chemokine expression levels. We detected 
significant reductions in E- and P-selectin and in Cxcl2 expression in TNF or 
TNF/zVAD treated Ripk1D138N/D138N mice; however, no consistent differences were 
observed in ICAM-1 or VCAM-1 expression (Figure 26, A and B). Although 
chemokine differences were less pronounced in TNF-treated livers, TNF/zVAD 
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treatment resulted in significant increases in Cxcl2 expression in WT compared to 
Ripk1D138N/D138N liver (Figure 26B), perhaps reflective of increased plasma IL-1β 
and IL-17α levels316–318. While decreased chemokine mRNA levels in 
Ripk1D138N/D138N lung and liver correlate with reduced neutrophil infiltration during 
TNF- and TNF/zVAD-induced shock (Figure 17, D and E), TNF- or TNF/zVAD-
induced adhesion molecule upregulation in vivo does not appear to require RIPK1 
kinase activity. 
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Figure 25. RIPK1 kinase activity is required for lung endothelial necroptosis 
induced by TNF/Smac/zVAD treatment but not for upregulation of adhesion 
molecules in endothelial cells in vitro. (A) Relative expression of ICAM-1, 
VCAM-1, E-selectin, P-selectin, Cxcl1 and Cxcl2 in WT and Ripk1D138N/D138N 
primary lung endothelial cells treated with TNF for 1 or 4 hours (n = 3-4 mice). 
Graphs show relative mRNA expression normalized to Actin. (B) Secretion of 
CXCL1 and CXCL2 in WT and Ripk1D138N/D138N primary lung endothelial cells 6 or 
22 hours after addition of TNF (n = 3-4 mice). (C) Primary lung endothelial cells 
isolated from WT and Ripk1D138N/D138N mice were treated with TNF (10 ng/ml), 
zVAD (20 μM), and/or Smac mimetic (1 μM) and cell viability was measured using 
MTS assay (n = 3 mice). Error bars represent mean ± SEM. *p<0.05, by 2-tailed 
Student’s t test. 
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Figure 26. Kinase inactive RIPK1 mice upregulate adhesion molecules and 
chemokines but exhibit decreased P-selectin and Cxcl2 expression in lung 
and liver treated with TNF or TNF/zVAD. Relative expression of E-selectin, P-
selectin, VCAM-1, ICAM-1, Cxcl1 and Cxcl2 in WT and Ripk1D138N/D138N lungs (A) 
or livers (B) after TNF (4 or 8h) or TNF/zVAD (4h) treatment (n = 3-4 mice). Graphs 
show relative mRNA expression normalized to Actin. *p<0.05, **p<0.01, 
***p<0.001, by 2-tailed Student’s t test. 
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RIPK1 kinase activity mediates TNF-induced liver endothelial cell 
necroptosis 
Since the kinase activity of RIPK1 was not required for endothelial cell 
activation, we hypothesized that RIPK1 kinase-regulated endothelial cell death 
may be responsible for the increase in vascular permeability, coagulation and 
organ damage observed in WT mice. To test whether endothelial cells undergo 
necroptotic death, we isolated primary lung endothelial cells from WT and 
Ripk1D138N/D138N mice and treated them with concentrations of TNF, Smac mimetic 
and zVAD known to induce necroptosis in murine embryonic fibroblasts44. Primary 
lung endothelial cells isolated from WT mice did not undergo TNF/Smac-induced 
apoptosis or TNF/zVAD-induced necroptosis but were susceptible to necroptosis 
induced by TNF/Smac/zVAD treatment (Figure 25C). In contrast, Ripk1D138N/D138N 
endothelial cells were resistant to TNF/Smac/zVAD-induced necroptosis (Figure 
25C). Collectively, these data demonstrate that RIPK1 kinase activity is required 
for TNF-induced endothelial necroptosis in vitro (Figure 25C), and for increased 
vascular permeability in vivo (Figure 22), implicating RIPK1 kinase-dependent 
endothelial cell necroptosis in SIRS.  
To examine this possibility, we stained liver sections with endomucin, an 
endothelial cell marker319, after TNF or TNF/zVAD administration (Figure 24D). In 
treated WT mice we detected breaks in the endothelial barrier, indicating 
endothelial cell loss and/or detachment, and increased permeability and 
extravasation of leukocytes and erythrocytes into the interstitial space (Figure 
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24D). TNF/zVAD treatment induced endothelial detachment with evidence of 
leukocyte adherence and translocation in all 3 WT mice examined, whereas these 
morphological changes were observed in 2 of 4 WT mice treated with TNF. These 
histopathologic findings were not evident in TNF- or TNF/zVAD-treated 
Ripk1D138N/D138N mice, where liver endothelial barrier integrity was maintained 
similarly to untreated mice (Figure 24D).  
Due to a lack of reliable measures of necroptotic death in mice, we isolated 
primary liver endothelial cells from TNF- and TNF/zVAD-treated WT and 
Ripk1D138N/D138N mice (80% average purity, Figure 27, A and B) and assessed 
MLKL activation. We consistently detected phospho-MLKL reactivity in endothelial 
cells isolated from TNF/zVAD-treated WT mice, but not in endothelial cells isolated 
from Ripk1D138N/D138N mice (Figure 24E). We were unable to detect phospho-MLKL 
reactivity in endothelial cells isolated from TNF-treated mice (Figure 28A), where 
endothelial breaks were observed only in half the mice examined (Figure 24D). 
Although unclear in the TNF shock model, TNF/zVAD-induced shock is mediated 
by RIPK1-dependent liver endothelial cell necroptosis. 
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Figure 27. Gating strategy and purity of endothelial cells isolated from TNF- 
or TNF/zVAD-treated WT and Ripk1D138N/D138N mice. (A) Gating strategy for the 
purification of liver endothelial cells using FACS. CD45+ cells were depleted before 
enriching for CD146+ cells and gating on CD45- CD31+ cells. (B) Quantification 
of liver endothelial cell enrichment from untreated (Unt.), or TNF or TNF/zVAD-
treated WT and Ripk1D138N/D138N mice (n = 3). Error bars represent mean ± SEM. 
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Figure 28. Phosphorylated MLKL is detected in liver endothelial cells from 
TNF/zVAD-treated but not TNF-treated mice, nor is cleaved caspase-3 
detected in TNF-treated livers. (A) WT and Ripk1D138N/D138N endothelial cells 
were isolated from livers of untreated, TNF-, or TNF/zVAD-treated mice. A 
representative western blot showing protein lysates probed with antibodies to 
phospho-MLKL, MLKL, ERK1/2 is depicted. Lysates from murine embryonic 
fibroblasts (MEF) left untreated (Unt.) or stimulated with TNF, SMAC mimetics, and 
zVAD-fmk (T/S/Z) served as a positive control. (Lysates were generated and 
analyzed from 7 WT and 7 Ripk1D138N/D138N TNF-treated mice). (B) Lysates from 
WT or Ripk1D138N/D138N liver endothelial cells isolated from untreated or TNF-treated 
mice were probed with antibodies to full length and cleaved caspase-3 (CC3) or 
ERK1/2 as a loading control. MEFs left untreated (Unt.) or treated with TNF and 
cycloheximide (T/Cx) served as controls for CC3 detection. (C) Quantification of 
cleaved caspase-3-positive liver endothelial cells from untreated or TNF-treated 
WT and Ripk1D138N/D138N mice by IHC (n = 3-6 mice per group). Error bars represent 
mean ± SEM. 
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Discussion 
Here we demonstrate that the resistance of RIPK1 kinase inactive mice to 
TNF- and TNF/zVAD-induced shock is not due to hematopoietic cells and/or 
“cytokine storm”, but rather due to lack of endothelial cell necroptosis, which 
prevents breaks in the vascular endothelium, activation of the clotting cascade and 
organ damage. Our results provide genetic evidence that RIPK1 kinase activity 
mediates liver endothelial cell necroptosis during TNF/zVAD-induced shock.  
Cytokines such as IL-1β and IL-17α, and both apoptotic and necroptotic cell 
death, have been implicated in TNF-induced lethality40,97,227,320,321. As reported 
previously in Nec-1 treated WT mice and Ripk3-/- mice97, we found 
cytokine/chemokine induction to be normal in TNF-treated Ripk1D138N/D138N mice, 
however these mice failed to sustain cytokine levels in response to TNF 
administration. Interestingly, we show that TNF/zVAD-induced shock augmented 
the proinflammatory response in WT but not Ripk1D138N/D138N mice (Figure 15B), 
supporting the notion that necroptosis amplifies proinflammatory signaling and 
exacerbates organ injury. Multiple studies have shown that RIPK3 deficiency or 
pharmacologic inhibition of RIPK1 kinase activity decreases serum levels of 
DAMPs such as mitochondrial DNA (mtDNA) or markers of organ injury such as 
creatinine kinase, aspartate aminotransferase, or lactate dehydrogenase97,322,323. 
Furthermore, DAMPs such as HMGB1 and extracellular histones are elevated in 
the blood of SIRS and sepsis patients, where they have been thought to result in 
chronic TLR activation and tissue injury324–326.  
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TNF/zVAD administration elevated IL-1β levels, which were not 
systemically increased with TNF treatment alone. Caspase-1 and caspase-1/11-
deficient mice, but not IL-1β/18-deficient mice, are susceptible to TNF-induced 
shock, thereby excluding a primary role for caspase-1-mediated inflammasome 
activation in TNF shock97,321. Two recent reports have implicated MLKL activation 
in initiating inflammasome-mediated processing and release of IL-1β327,328, 
suggesting that necroptosis sensitization in TNF/zVAD-induced shock and MLKL 
activation may contribute to increases in plasma IL-1β levels. 
In addition to cell death signaling, RIPK1 kinase activity has been implicated 
in cytokine/chemokine production in vitro103,277,278, including reduced transcription 
and production of CXCL1 in TNF/zVAD-treated kinase inactive Ripk1K45A/K45A 
BMDMs24. In agreement with these recent reports, we find CXCL1, CXCL2 and IL-
6 transcription and secretion impaired in vitro in TNF/zVAD-treated 
Ripk1D138N/D138N BMDMs (Figure 16), suggesting that reductions in the cytokine 
response in RIPK1 kinase inactive mice are due to effects of RIPK1 kinase activity 
on cytokine production rather than necroptotic cell death. With the exception of 
CXCL2, however, cytokine/chemokine production at early time points is unaffected 
by a lack of RIPK1 kinase activity (Figures 15 and 20), demonstrating that in vivo, 
RIPK1 kinase activity is not required for cytokine/chemokine induction in response 
to a high dose of TNF. Significant reductions in plasma cytokine/chemokine levels 
were observed in TNF-treated Ripk1D138N/D138N mice at 7h, consistent with the 
proinflammatory nature of necroptotic death. Additionally, Ripk1D138N/D138N  WT 
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chimeras had elevated cytokine/chemokine levels in response to TNF/zVAD 
administration (Figure 21), suggesting that RIPK1 kinase activity does not regulate 
cytokine/chemokine production when caspases are inhibited in vivo. 
We found that 3 of 11 Ripk1D138N/D138N  WT chimeras recovered from 
TNF/zVAD administration (Figure 18E), indicating that Ripk1D138N/D138N 
hematopoietic cells can contribute to protection. Our data suggests that optimal 
cytokine/chemokine induction requires necroptosis competent (WT) hematopoietic 
and endothelial cells (Figure 20A), leading us to speculate that DAMPs released 
by necroptotic endothelial cells feedback on WT hematopoietic cells to induce 
necroptosis and further amplify cytokine levels. Thus, Ripk1D138N/D138N 
hematopoietic cells may mediate recovery in Ripk1D138N/D138N  WT chimeras by 
failing to undergo necroptosis in response to DAMPs released by WT necroptotic 
endothelial cells. Alternatively, recovery may be mediated by the survival of 
Ripk1D138N/D138N hematopoietic cells and production of anti-inflammatory cytokines 
which support barrier repair.  
A caveat of our bone marrow chimera studies is that protected WT  
Ripk1D138N/D138N mice retain radiation-resistant, tissue resident Ripk1D138N/D138N 
macrophages such as Kupffer cells (KC) in the liver. KC associate with endothelial 
cells in the liver sinusoids and function to maintain liver homeostasis by surveying 
microbial products from the intestine. KC express TLRs and produce cytokines and 
chemokines in response to DAMPs or pathogen associated molecular patterns 
(PAMPs). Moreover, KC undergo necroptosis upon Listeria monocytogenes 
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infection329.  Thus, Ripk1D138N/D138N KC may contribute to resistance to shock by 
failing to undergo necroptosis and/or produce cytokine/chemokines in response to 
microbial products or DAMPs released by necroptotic endothelial cells.  
Although we detect decreases in cleaved caspase-3 positive ileal but not 
colonic IECs in TNF-treated Ripk1D138N/D138N mice, no significant differences in 
intestinal apoptosis were observed between TNF/zVAD-treated WT or 
Ripk1D138N/D138N mice (Figure 23). Consistent with these data, executioner 
caspases -3 or -7 and TNFR1-mediated IEC apoptosis do not appear to contribute 
to TNF-induced lethality97,313. However, Newton et al. show that while there is 
evidence of slight hypothermia in Ripk3-/- and Mlkl-/- mice in response to TNF, 
Ripk3-/- Caspase-8-/- and Mlkl-/- Caspase-8-/- double-knockout mice are completely 
protected from TNF-induced hypothermia and have significantly reduced serum 
cytokine and chemokine levels227. Additionally, they show that Caspase-8+/- and 
Villin-cre Ripk3fl/fl mice are largely protected from TNF-induced 
cytokine/chemokine expression and hypothermia, suggesting that in addition to 
necroptosis, caspase-8 contributes to lethality during TNF-induced shock227. Since 
our data and others indicate no role for the caspase-1-mediated inflammasome or 
intestinal apoptosis in TNF-induced lethality97,313, caspase-8 mediated effects 
likely reflect its role(s) in inflammasome-independent IL-1β regulation and 
processing330.  
 Although TNF shock is typically thought of as a sterile model of injury, 
several reports show a key role for intestinal barrier dysfunction and systemic 
112 
 
 
 
spread of bacteria in the blood of TNF-treated mice312,313. While not addressed in 
the Newton study, the Villin-cre Ripk3fl/fl mice may be protected from hypothermia 
and increased cytokine levels because RIPK3-deficient IECs fail to undergo 
necroptosis and consequently the intestinal epithelial barrier is maintained. We 
show that Ripk1D138N/D138N mice do not exhibit TNF-induced increases in intestinal 
permeability, nor do we detect spread of bacteria to peripheral organs such as the 
liver or spleen. While breaches in the intestinal epithelium and entry of bacteria or 
bacterial products into the bloodstream may contribute to TNF-induced shock, our 
data demonstrate that the downstream effects of the host response converge on 
the vascular endothelium.  
We find that TNF-resistant Ripk1D138N/D138N mice and WT  Ripk1D138N/D138N 
chimeras do not exhibit increases in lung and liver vascular permeability, or 
evidence of increased tissue factor expression and coagulation. Furthermore, in 
the TNF/zVAD model, vascular barrier protection and an absence of coagulation, 
at least in the liver, correlate with an inability to detect phospho-MLKL reactivity in 
the protected RIPK1 kinase inactive endothelium. Our results indicate that 
necroptosis contributes to barrier disruption and activation of the clotting cascade, 
as we find MLKL activation in liver endothelial cells isolated from TNF/zVAD-
treated WT mice.  
Although TNF and TNF/zVAD treatment increase plasma tissue factor 
levels (Figure 22D) and induce coagulation (Figure 24, A and B), we detect fewer 
breaks in the liver endothelium of TNF-treated WT mice (Figure 24D). Consistent 
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with this observation, we were unable to detect phospho-MLKL reactive endothelial 
cells in livers of TNF-treated mice (Figure 28A). We hypothesized that TNF may 
stimulate RIPK1-kinase-dependent apoptosis, however, cleaved caspase-3 
reactive cells were not detected in TNF-treated liver sections by 
immunohistochemistry or by immunoblotting endothelial cell lysates from TNF-
treated mice (Figure 28, B and C), suggesting that apoptosis is not responsible for 
the vascular breaks. In contrast to TNF/zVAD administration where hypothermia 
and lethality is rapid and fully penetrant in WT controls (Figures 8, 9, and 18), mice 
treated with TNF take longer to exhibit symptoms (hypothermia, inactivity, hunched 
posture) and are variable in their presentation at sacrifice, 8 hours post TNF 
administration. We speculate that our inability to detect phospho-MLKL-reactive 
endothelial cells in mice treated with TNF reflects this variability in presentation 
and consequently fewer endothelial breaks (Figure 24D) and potentially less 
endothelial cell necroptosis was induced following TNF treatment for 8 hours 
compared to TNF/zVAD treatment for 4 hours.  
We also demonstrate that lung endothelial cells isolated from WT but not 
Ripk1D138N/D138N mice undergo necroptosis in vitro when treated with TNF, Smac 
and zVAD, but not with TNF/zVAD only (Figure 25C). This finding was unexpected 
as TNF/zVAD administration is sufficient to induce liver endothelial cell necroptosis 
in vivo (Figure 24E). The requirement for Smac mimetic to induce endothelial 
necroptosis in vitro may reflect increased cellular pools of cIAP1/2 or XIAP in lung 
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versus liver endothelial cells or simply indicate that TNF/zVAD concentrations 
achieved in vivo are not accurately modeled in vitro. 
Many septic patients have impaired endothelial barrier function, exhibit 
edema, coagulation abnormalities, and decreased levels or dysfunctional 
activation of anticoagulants. The most promising clinical trials have focused on 
combining anti-inflammatory and anticoagulant agents, such as activated protein 
C or thrombomodulin331. Recent advances focus on methods to strengthen the 
vascular endothelium and modulate its response to proinflammatory cytokine 
levels. In several models of LPS endotoxemia or cecal ligation and puncture (CLP), 
enhanced vascular stability dramatically increased mouse survival, even though 
no reductions in the proinflammatory cytokine response were observed332,333. 
Similarly, we demonstrate that chimeric mice susceptible to TNF-induced shock 
exhibit increased vascular permeability and coagulation even when 
proinflammatory cytokine levels are not sustained (Figure 20A, and Figure 22, E 
and F). We provide evidence that Ripk1D138N/D138N liver endothelial cells fail to 
exhibit MLKL activation and undergo necroptosis (Figure 24E), thereby 
maintaining an intact vasculature that protects RIPK1 kinase inactive mice from 
TNF/zVAD-induced lethality. Interestingly, RIPK3 plasma levels are significantly 
increased in non-survivors of sepsis334, suggesting that endothelial cell 
necroptosis may contribute to lethality in both SIRS and sepsis patients. 
Ripk1D138N/D138N, Ripk3-/- and Mlkl-/- mice have been examined in mouse models of 
sepsis and although the results generated using the cecal ligation and puncture 
115 
 
 
 
model are conflicting48, 97, 335, we and others find Ripk1D138N/D138N mice susceptible 
to LPS administration (227, and Figure 11), indicating that necroptosis may not be 
a critical factor in sepsis. The role of necroptosis in shock and sepsis needs to be 
explored further, but our results demonstrate that RIPK1 kinase inhibitors may 
have promise in ameliorating or preventing inflammatory vascular injury and SIRS.  
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Methods 
Mice  
Ripk1D138N/D138N mice were described previously40. For bone marrow 
transplantation studies, recipient C57BL/6 CD45.1 or CD45.2 (WT or 
Ripk1D138N/D138N) mice received 11 Gy of total body irradiation in a split dose (550 
rads) using a Cesium-137 irradiator, with a 4-hour rest between doses. Irradiated 
recipients were reconstituted by intravenous injection of 2x106 WT (CD45.1 or 
CD45.2) or Ripk1D138N/D138N (CD45.2) bone marrow cells. Recipients were 
maintained on medicated water for one month. Cheek bleeds were performed after 
4 and 8 weeks to assess reconstitution efficiency by flow cytometry.  
 
TNF-induced shock experiments 
Male WT and Ripk1D138N/D138N littermates were injected intravenously with 9 
μg mTNFα (Cell Sciences) only or in combination with 16.7 mg/kg zVAD-fmk 
(Bachem), unless noted otherwise. Body temperature and survival were monitored 
every few hours. Mice were used between 8 and 12 weeks of age. For ex vivo 
analyses mice were typically sacrificed after 4 (TNF/zVAD) or 8 hours (TNF). 
Reconstituted mice were injected with mTNFα and zVAD-fmk 2 months after 
reconstitution. When littermate controls were not used, sex- and age-matched 
mice were co-housed.  
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Cytokine Analysis 
Plasma cytokines were measured using a 12-plex protein/peptide multiplex 
analysis (Luminex Technology) conducted by the National Mouse Metabolic 
Phenotyping Center at the University of Massachusetts Medical School. Cytokines 
and chemokines that were below the limit of detection were assigned a value of 
zero. Blood was collected via cardiac puncture in a heparinized needle and spun 
down to isolate plasma. The samples were stored at -80°C until analysis. Plasma 
tissue factor levels were determined by ELISA (R&D Systems). IL-6 (eBioscience), 
CXCL1, CXCL2, and CCL5 (R&D Systems) secretion by cultured primary cells was 
determined by ELISA.  
 
Gene expression Analysis  
Primary BMDMs were treated with 50 ng/mL TNF (R&D Systems) or TNF 
and 50 μM zVAD (Enzo) for 2 or 6 hours. Primary lung endothelial cells were 
treated with TNF (100 ng/mL) for 1 or 4 hours. Total cellular RNA was isolated 
using an RNeasy Mini Kit (QIAGEN). Total lung or liver RNA was extracted with 
TRIzol (Life Technologies). cDNA was prepared using the Superscript First-Strand 
Synthesis System (Invitrogen). Quantitative real-time PCR was performed using 
Power SYBR Green PCR Master Mix (Applied Biosystems) and run on the AB7300 
Detection System (Applied Biosystems). Relative gene expression was normalized 
to Actin and determined using the CT method, with the following primer 
sequences: 
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Gene symbol Direction Primer sequence (5' to 3') 
Actin For CGAGGCCCAGAGCAAGAGAG 
Rev CGGTTGGCCTTAGGGTTCAG 
E-selectin For ATGCCTCGCGCTTTCTCTC 
Rev GTAGTCCCGCTGACAGTATGC 
P-selectin For CATCTGGTTCAGTGCTTTGATCT 
Rev ACCCGTGAGTTATTCCATGAGT 
ICAM-1 For GTGATGCTCAGGTATCCATCCA 
Rev CACAGTTCTCAAAGCACAGCG 
VCAM-1 For AGTTGGGGATTCGGTTGTTCT 
Rev CCCCTCATTCCTTACCACCC 
Il6 For AACGATGATGCACTTGCAGA 
Rev GAGCATTGGAAATTGGGGTA 
Ccl5 For GCCCACGTCAAGGAGTATTTCTA 
Rev ACACACTTGGCGGTTCCTTC 
Cxcl1 For CTGGGATTCACCTCAAGAACATC 
Rev CAGGGTCAAGGCAAGCCTC 
Cxcl2 For CCAACCACCAGGCTACAGG 
Rev GCGTCACACTCAAGCTCTG 
 
Flow Cytometry 
Single-cell suspensions from blood, spleen, bone marrow, lung and liver 
were stained with cell-surface antibodies for myeloid (Gr-1, CD11b, CD11c, and 
Ly-6C), lymphoid (CD4, CD8, and B220) and endothelial (CD31) markers. To 
distinguish between donor and host hematopoietic cells in the bone marrow 
reconstitution experiments, anti-CD45.1 and anti-CD45.2 antibodies were used. 
DAPI (Molecular Probes) was used to distinguish between live and dead cells. All 
samples were run on a BD LSRII flow cytometer (BD Bioscience) and analyzed 
using FlowJo software (Tree Star) with the following antibodies: 
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Antibody Clone Fluorophore Source 
CD11b M1/70 FITC BioLegend 
Gr-1 RB6-8C5 PE BD Biosciences 
Ly-6C HK1.4 APC BioLegend 
Cd11c N418 Pacific Blue BioLegend 
CD45.1 A20 PerCP/Cy5.5 BioLegend 
CD45.2 104 PeCy7 BioLegend 
CD4 RM4-5 PerCP/Cy5.5 BioLegend 
CD8 53-6.7 FITC BD Biosciences 
B220 RA3-6B2 PE BioLegend 
CD45 30-F11 APC-Cy7 BD Biosciences 
CD31 390 FITC BioLegend 
 
Prothrombin Time Test 
Blood was collected via cardiac puncture and mixed with 3.2% sodium 
citrate in a 9:1 ratio. Plasma was isolated and the test was conducted by IDEXX 
(Grafton, MA). 
 
Vascular Permeability Assay   
A 1% Evans Blue (Sigma) solution was injected iv at 40 mg/kg six hours 
after mTNF-α administration. After 1 hour the mice were sacrificed, perfused and 
organs were dried overnight before homogenization in formamide (Sigma). The 
amount of extracted Evans Blue dye was assessed by spectrophotometry at 
620nm on a Beckman Coulter DTX880 plate reader. 
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Intestinal Permeability Assay  
Mice were orally gavaged with 100 μL of 150 mg/kg Fluorescein 
isothiocyanate-dextran (M.W. 4000) beads (Sigma) 2 hours after TNF 
administration. 6 hours later blood was drawn via cardiac puncture. The amount of 
FITC-dextran in plasma was measured on a Beckman Coulter DTX880 plate 
reader (excitation wavelength: 488 nm, emission wavelength: 530 nm). 
 
Histology and Immunohistochemistry 
Livers were fixed in 2% paraformaldehyde (Fisher Scientific). Samples were 
embedded in paraffin and H&E staining was done on 8 μm thick sections according 
to standard protocols. Cleaved caspase-3 staining was done on 6-micron thick 
sections at 1:100 dilution of cleaved caspase-3 antibody (cat # 9661, Cell 
Signaling) according to standard protocols. For endomucin staining, 3 μm thick 
liver sections were processed through xylene and rehydrated through an ethanol 
gradient prior to immersion in sodium citrate buffer (10 mM sodium citrate, 0.05% 
Tween 20, pH 6) and antigen retrieval was done using a 2100 Antigen retriever. 
Sections were incubated for 1hr at room temperature (RT) in blocking solution (1% 
rabbit serum, 1% BSA, 0.3% Triton-X 100 in PBS), and then kept in primary 
antibody mix (Endomucin, 1:200, Santa Cruz sc-65495; in 2.5% rabbit serum in 
PBS) overnight at 4°C. Rat secondary antibody was used for 1 hour at room 
temperature (Vector biotinylated anti-rat IgG). Sections were developed using 
Vectastain Elite ABC Kit and DAB Peroxidase Substrate Kit according to 
manufacturer’s instructions (Vector Laboratories) before counterstaining with 
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Hematoxylin and mounting with Vectashield dry mounting media. Images were 
acquired using a Nikon Eclipse 80i microscope. To quantify the percentage of 
clotting in liver blood vessels, 8 random fields at 20x field of view were counted per 
mouse. To quantify the percentage of cleaved caspase-3 positive cells in the 
intestines, 10 random fields at 40x field of view were counted per mouse. To 
quantify the number of cleaved caspase-3 positive cells in the intestines or liver, 
10 random fields at 40x field of view were counted per mouse. 
 
Cell culture 
BMDMs were generated by culturing bone marrow cell suspensions in 20% 
conditioned media from L929 cells for seven days. On day 7 adherent cells were 
re-plated in 6-well plates for mRNA experiments (2x106 cells per well) or in 96-well 
plates for ELISA assays (2x105 cells per well). Mouse lungs were digested in 25 
mL of 1 mg/mL collagenase at 37°C for an hour. After sequential filtering through 
a 100 μm and 40 μm cell strainer, the cell suspension was plated on a gelatin-
coated T75 flask and the cells were incubated for 4-6 days until reaching 
confluence. Cells were grown in endothelial cell media containing low glucose 
DMEM/F-12 with 20% FBS, 1% L-glutamine, 1% Pen-Strep, 100 μg/mL Heparin 
and 50 μg/mL endothelial cell growth supplement (Biomedical Technologies Inc.). 
To immunoselect endothelial cells, confluent T75 flasks were incubated with CD-
31 (PECAM-1, cat # 553369, BD Biosciences) and CD102-coated (ICAM-2, cat # 
553325, BD Biosciences) Dynabeads on ice for 20 minutes. Using a magnetic 
122 
 
 
 
separator, bead-bound cells were recovered and washed 3 times with PBS. 
Endothelial cells were plated on gelatin-coated T25 flasks and expanded. 
 
Liver endothelial cell isolation 
 Mice were pefused with PBS, livers were minced with a razor blade on ice, 
and shaken for 30 minutes at 37°C in 1 mg/mL collagenase. The suspension was 
filtered through a 100 μm strainer and spun for 5 minutes at 50g to separate out 
hepatocytes. The supernatant was spun again for 5 minutes at 60g before the non-
parenchymal cell fraction in the supernatant was pelleted at 700g for 10 minutes. 
After red blood cell lysis, the non-parenchymal liver cell fraction was depleted of 
CD45+ positive cells before enriching for CD146+ endothelial cells with MACS 
MicroBeads, according to manufacturer’s instructions (Miltenyi Biotec). Purity was 
checked by FACS and recovered cells were snap frozen to use for Western blot. 
 
Immunoblotting 
Isolated liver endothelial cells were lysed in RIPA buffer (150 mM NaCl, 50 
mM Tris-HCl (pH 7.5), 1% NP40, 0.25% deoxycholate, 0.1% SDS, 1 mM EDTA), 
supplemented with protease inhibitors (Roche Applied Science), supplemented 
with sodium orthovanadate (1 mM), phenylmethylsulfonyl fluoride (PMSF, 1 mM), 
and dithiothreitol (DTT, 1 mM). Total protein was run on a 10% SDS-PAGE gel, 
transferred to a nitrocellulose membrane (Invitrogen) and probed with antibodies 
to phospho-MLKL (ab196436, Abcam), MLKL (gift from Jiahuai Han, and 
AP14272b, Abgent), caspase-3 (cat # 9662, Cell Signaling), and ERK1/2 (cat # 
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9102, Cell Signaling). Membranes were developed with Clarity Western ECL 
Substrate (BioRad). 
 
 
Cell viability 
For apoptosis and necroptosis assays, cultured lung endothelial cells were 
pre-treated with 1 μM Smac mimetic (ChemieTek) or 20 μM zVAD-fmk (Enzo) prior 
to adding TNF (10 ng/mL). Metabolic activity was assayed after 20 hours by 
addition of MTS reagent (CellTiter 96 AQueous One Solution Cell Proliferation 
Assay, Promega) and measured using a Beckman Coulter DTX880 plate reader. 
Absorbance values at 535nm were normalized to Smac mimetic control. 
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CHAPTER V 
 
 
 
 
 
 
 
 
Discussion 
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This thesis research has focused on elucidating the role of RIPK1 kinase 
activity in regulating pro-inflammatory and pro-death signaling in response to 
TNFR1 or TLR3/4 activation. I demonstrate that the kinase activity of RIPK1 
contributes to necrosome formation and regulates both apoptosis and necroptosis 
induction in response to certain stimuli in MEFs and BMDMs. I have shown that 
RIPK1 kinase activity regulates transcriptional and/or translational activation of 
TNF/zVAD-induced cytokines and chemokines in vitro, but does not play a role in 
their regulation in vivo. Additionally, the lack of RIPK1 kinase activity mediates 
protection from TNF- and TNF/zVAD-induced shock by critically acting in non-
hematopoietic lineages, protecting the intestinal epithelial and vascular endothelial 
barriers from permeability increases and clotting, in part by abrogating endothelial 
cell necroptosis. Thus, this work disproves the cytokine storm idea and helps clarify 
the role of RIPK1 kinase activity in driving TNF-induced inflammation and shock in 
mice via necroptosis and effects on the endothelium. 
 Early studies of the serine/threonine kinase RIPK1 identified its prominent 
role in proinflammatory and cell survival signaling downstream of TNFR1 and 
TRIF-dependent TLRs 3/4 by acting as a scaffold to mediate optimal NF-κB and 
MAP kinase pathway activation. Though these functions were kinase-independent, 
RIPK1 was found to have additional kinase-dependent death roles, as it could 
induce caspase-8 dependent apoptosis or caspase-independent 
RIPK1/RIPK3/MLKL-mediated necroptosis. However, most of these studies were 
done with in vitro reconstitution of kinase inactive RIPK1 mutants, or utilizing the 
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original, less specific and less potent, Nec-1 inhibitor289. Especially in vivo, the role 
of RIPK1 kinase activity was unclear as Nec-1 was determined to either sensitize 
or protect mice in an inflammatory TNF-induced shock model97–99. To determine 
the role of RIPK1 kinase activity in mediating inflammation and necroptosis in vivo, 
we generated kinase inactive Ripk1D138N/D138N mice and examined their responses 
to pro-apoptotic and pro-necroptotic stimuli in vitro and in vivo. 
 Our work in chapter 2 demonstrated that the kinase activity of RIPK1 is 
required for efficient necrosome formation with RIPK3, and for mediating 
TNF/Cx/zVAD or TNF/Smac/zVAD-induced necroptosis in MEFs. Previous studies 
have suggested that RIPK3 is recruited into the initial pro-apoptotic complex IIb or 
Ripoptosome to form the necrosome43,44,161,162. However, it remains unclear 
whether when pulling down the complex with caspase-8 or RIPK3 antibodies we 
detect the same cytosolic complex, or different cytosolic pools of these interacting 
necrosome components. RIPK1 and RIPK3 are reported to oligomerize and form 
amyloid fibrils upon necroptotic stimulation201, and indeed in instances of complex 
formation we consistently detected decreased levels of the complex components 
caspase-8, RIPK1, and RIPK3 in the whole cell lysate. This suggests that the 
necrosome is indeed oligomerizing and we are not solubilizing it efficiently with our 
Triton X-100 detergent used in the endogenous lysis buffer. Several studies have 
shown that the RIPK1/RIPK3 necrosome preferentially localizes to a Triton/NP-40-
insoluble, SDS- or urea-soluble fraction in vitro and ex vivo203,294. Thus, varying 
the detergents in our immunoprecipitations or lysing the insoluble fraction with a 
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harsher detergent may reveal additional qualitative or quantitative differences in 
the caspase-8/RIPK1/RIPK3 necrosome complex. 
Interestingly, our data show that RIPK3 kinase activity is not necessary for 
RIPK3 recruitment or for stable formation of a TNF/Smac/zVAD-induced 
necrosome complex that includes caspase-8 and presumably FADD (Figure 5). 
While RIPK3 kinase activity was not required for stable complex formation, it was 
required to induce necroptosis in TNF/Smac/zVAD-stimulated MEFs. A similar 
scenario has been reported in TNF/Cx/zVAD-stimulated MEFs322. While Nec-1 
blocked necrosome assembly, the RIPK3 kinase inhibitors did not affect 
necrosome assembly but were required for the induction of necroptotic death322. 
Thus, in TNF/Cx/zVAD- or TNF/Smac/zVAD-treated MEFs, necrosome formation 
requires the kinase activity of RIPK1 but not RIPK3, although the kinase activities 
of both are required for necroptosis to ensue322. These results suggest that RIPK1 
kinase activation and conformational change allows it to auto-phosphorylate and 
recruit RIPK3 via RHIM-mediated interactions to the necrosome. Although RIPK3 
can phosphorylate RIPK1 in vitro43,87, this trans-phosphorylation event does not 
seem necessary for stable RIPK1/RIPK3 interaction in this context. Use of the 
RIPK3 kinase inhibitors, instead of a kinase inactive RIPK3, may cause 
conformational changes that promote the interaction of RIPK3 with RIPK1, FADD, 
and caspase-8228,272. Additional experiments interrogating the role of RHIM mutant 
and kinase inactive RIPK1 and RIPK3 in mediating stable necrosome formation in 
MEFs would be informative to elucidating the importance of RIPK1 and RIPK3 in 
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recruitment and auto- and trans-phosphorylation of the necrosome components. 
Utilizing RIPK1 kinase inactive mice, we were able to definitively prove that 
RIPK3 and RIPK1 kinase activity play crucial roles in mediating TNF- and 
TNF/zVAD-induced shock or SIRS (Figures 8 and 9), in agreement with Duprez et 
al97. Similarly, RIPK1 kinase inactive mice seemed partially protected from lower 
doses of LPS-induced hypothermia and lethality, in line with the prominent LPS-
induced TNF upregulation that occurs in vivo (Figure 12). However, a higher LPS 
dose was not protective and importantly, RIPK1 kinase inactive littermates were 
sensitized to LPS-induced hypothermia. Thus, using littermate controls in these 
shock studies is critically important as microbiota differences exist even between 
age-, sex- and strain-matched non-littermate mice302. Recently, several groups 
identified caspase-11 as sensing cytoplasmic LPS and activating a non-canonical 
inflammasome, mediating pyroptosis and IL-1β/IL-18 release. Indeed, caspase-
11-deficient and IL-1β/IL-18 double knock-out mice were largely resistant to LPS-
induced shock321,336–338. Our LPS shock data suggest that RIPK1 kinase activity 
does not play a role in this caspase-11-dependent pathway, consistent with a 
recent report that Ripk1D138N/D138N and Ripk3-/- littermates are susceptible to LPS 
but not TNF-induced shock227. Interestingly, RIPK1 K45A kinase inactive mice are 
partially, but significantly, protected from high dose LPS-induced lethality278, 
suggesting that specific RIPK1 mutations and potential conformational changes, 
or microbiota differences in mice, may reveal some dependence of LPS-induced 
shock on RIPK1 kinase activity.  
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While our work implicates MLKL activation and endothelial necroptosis in 
TNF/zVAD-induced shock, a recent study has demonstrated that during LPS-
induced shock caspase-11-mediated endothelial cell pyroptosis in lungs leads to 
acute lung injury, increases in lung vascular permeability, neutrophil infiltration, 
and death339. Interestingly, both necroptosis and pyroptosis execution involves 
oligomerization and translocation of channel or pore-forming proteins to the 
plasma membrane. While MLKL oligomerization is activated by RIPK3-mediated 
phosphorylation, the pyroptosis executioner protein gasdermin-D is activated and 
oligomerizes upon caspase-1 or caspase-11-mediated proteolytic cleavage58–60. 
This releases the N-terminal p30 fragment, typically in an autoinhibitory 
conformation with the C-terminal region, allowing it to oligomerize and translocate 
to the plasma membrane where, like MLKL, it binds phosphatidylinositol 
phosphates and forms pores340–343. Interestingly, while MLKL is thought to form 
ion-selective channels leading to cation influx and swelling and bursting of the 
plasma membrane, N-terminal gasdermin-D fragment oligomerization seems to 
form non-selective ion-permeable pores343. Plasma membrane rupture during 
pyroptosis is not accompanied by swelling and the cells produce pyroptotic bodies 
prior to rupture343. Thus, while multiple forms of regulated necrosis may affect 
endothelial cell function and/or viability and contribute to lethality in mouse models 
of TNF- or LPS-induced shock, the differential effects of their plasma membrane 
rupture in vivo remain to be elucidated further. 
RIPK1 kinase activity has been implicated in LPS-induced inflammatory 
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gene regulation in vitro and in vivo, mediated in part by RIPK1 and RIPK3 kinase-
dependent regulation of ERK, cFos, NF-κB, and STAT1 activation277,278. We 
observed diminished upregulation of TNF and IL-1β levels in the blood of non-
littermate RIPK1 D138N kinase inactive mice treated with 5mg/kg LPS (Figure 12), 
similar to a report in RIPK1 K45A mice278. More fine-tuned regulation by RIPK1 
D138N kinase activity specifically in bone marrow CD11b+ macrophages was 
demonstrated with a sub-lethal LPS dose, which revealed reduced transcription 
and secretion of LPS-induced TNF, CCL3, CCL4, GM-CSF, and IL-6 in RIPK1 
kinase inactive mice277. We could confirm an LPS/zVAD- but not LPS-induced 
transcriptional regulation of Tnf and Csf2 in  Ripk1D138N/D138N BMDMs, but no clear 
effect on TNF- or IL-1β induced secretion as reported in the literature277,278. 
Additionally, in vivo differences in RIPK1 kinase-dependent cytokine/chemokine 
levels were observed with LPS stimulation alone, whereas in vitro regulation 
depended on caspase inhibition with zVAD in our work and the Najjar et al., but 
not Shutinoski et al. studies277,278. These discrepancies need to be addressed with 
additional experiments but may reflect inherent differences in conformational 
changes of RIPK1 or degree of kinase inhibition of the D138N and K45A mutations. 
Additionally, caspase-8 activity may be different in vitro and in vivo, thereby 
explaining why caspase inhibition with zVAD is not necessary to reveal RIPK1 
kinase-dependent regulation in mice277. In summary, our data suggests that RIPK1 
kinase activity regulates LPS/zVAD-induced Tnf and Csf2 upregulation in vitro and, 
at lower doses, LPS-induced cytokine levels in vivo. 
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We found that TNF-induced upregulation of cytokine/chemokine levels in 
vivo did not depend on RIPK1 kinase activity for transient induction, but seemed 
required for sustained inflammation (Figure 15A). This suggests that at lethal TNF 
doses, RIPK1 kinase activity does not have a regulatory role in 
cytokine/chemokine production, but that sustained inflammation is reduced due to 
lack of necroptosis and DAMP release. Similar to the dichotomy between LPS and 
LPS/zVAD-induced responses in vitro and in vivo, we observed TNF/zVAD-
induced RIPK1 kinase-dependent transcriptional and translational regulation of 
CXCL1, CXCL2, and IL-6 in primary BMDMs in vitro. Interestingly, CXCL2 levels 
were reduced in RIPK1 kinase inactive cells or mice in response to TNF alone, 
suggesting transcriptional regulation by a RIPK1 kinase-dependent mechanism 
that is unclear at this point. Our in vitro data supports a RIPK1 kinase-dependent 
role for TNF/zVAD-induced regulation of CXCL1 and demonstrates a novel role in 
IL-6 regulation, but could not confirm a role in CCL5 regulation24,278. Since these 
in vitro effects appear to be death-independent, future studies will need to resolve 
discrepancies as to what specific cytokines/chemokines RIPK1 kinase activity 
regulates in a transcriptional or translational manner, and what the mechanism of 
this regulation is in BMDMs in vitro. Importantly, our in vivo data argues that RIPK1 
kinase-dependent necroptosis, and not cytokine regulation, drives sustained 
inflammation via DAMP release.  
Our bone marrow chimera studies demonstrate that RIPK1 kinase activity 
in non-hematopoietic lineage/s drives TNF- and TNF/zVAD-induced shock, 
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contrary to the expectation that hematopoietic cell-mediated cytokine storm is a 
main mediator of lethality303. Indeed, we observed that TNF sensitive 
Ripk1D138N/D138N  WT mice exhibit reduced proinflammatory cytokine/chemokine 
levels as the shock progresses. However, IL-17R-deficient and IL-1β/IL-18 double 
knock-out mice are protected from a lethal TNF and/or LPS-induced shock320,321. 
Additionally, IL-1β and IL-17α levels are found increased in septic patients308,309 
and were elevated systemically in WT mice treated with TNF/zVAD, but not TNF 
(Figure 15). Thus, although our data indicates that the cytokine storm may not be 
the main driver of lethality, the importance of certain cytokines/chemokines, such 
as IL-17α, IL-1β, and IL-18 should not be over-looked. Since we determined 
cytokine/chemokine levels systemically in the plasma, it remains possible that 
there are differences in the systemic versus local tissue or organ inflammatory 
responses in WT and RIPK1 kinase inactive mice. For instance, is IL-17α 
expression increased in the intestines of TNF-treated WT mice but not detected 
systemically320?  
The levels of various organ damage markers, DAMPs, and cytokines are 
reduced in TNF-treated RIPK3-deficient mice compared to WT controls97. 
Meanwhile, we observed that kinase inactive RIPK1 mice are protected from TNF-
induced intestinal epithelial and vascular endothelial permeability increases and 
tissue factor upregulation and clotting. We were able to show that resistant 
reconstituted WT  Ripk1D138N/D138N mice are also protected from increases in 
tissue factor expression and vascular permeability. Although we detected evidence 
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of endothelial cell necroptosis in TNF/zVAD-treated mice via pMLKL activation, we 
could not detect endothelial cell apoptosis (cleaved caspase-3 positive cells) or 
necroptosis (pMLKL activation) in TNF-treated mice (Figure 28). Thus, while the 
TNF- and TNF/zVAD-mediated effects seem to converge on the endothelium, and 
necroptotic death of endothelial cells contributes to the induction of clotting, it is 
unclear what type(s) of cell death occur during TNF-induced shock. We could 
address this by looking at levels of organ damage markers and DAMPs (such as 
mitochondrial DNA) in TNF- and TNF/zVAD-treated non-reconstituted and 
reconstituted mice. Additionally, the development of a phospho-MLKL antibody 
suitable for flow cytometry assays or optimized for immunohistochemical staining 
will allow us to more definitively identify necroptotic cells. While we detected 
pMLKL reactivity in TNF/zVAD-treated endothelial cells, we could not detect 
evidence of MLKL activation in TNF- or TNF/zVAD-treated CD45+ hematopoietic 
cells isolated from the liver (data not shown). Thus, WT hematopoietic cells may 
not respond to DAMPs or undergo necroptosis during TNF-induced shock, while 
endothelial cells seem sensitized to necroptosis.  
A recent study showed that necroptosis is less inflammatory in vitro and in 
vivo compared to TNF or LPS stimulation because necroptotic death of the cells 
terminates the potent TNF- or LPS-driven proinflammatory signaling pathways64. 
While seemingly at odds with our conclusions, there are several differences 
between our studies that may explain these discrepancies. Kearney and 
colleagues inject supernatant from TNF- or TNF/zVAD-stimulated necroptotic 
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L929 cells into the peritoneal cavity of immunocompetent Balb/c mice and observe 
reduced infiltration of inflammatory cells in response to supernatant from 
necroptotic compared to TNF-stimulated cells64. While necroptotic supernatant 
contained reduced levels of inflammatory cytokines and chemokines prior to 
injection (due to high levels of cell death), we see systemic as well as organ-
specific increases in proinflammatory cytokines and the chemokines CXCL1 and 
CXCL2 with TNF/zVAD treatment via intravenous injection compared to TNF 
alone. Thus, in vivo, a systemic pro-necroptotic TNF/zVAD stimulus is more 
proinflammatory compared to TNF alone. The type and amount of DAMPs 
released by various cells in vivo or their modulation may be different than DAMPs 
released by a cell line in vitro. Additionally, our reconstitution data argues that non-
hematopoietic lineages drive TNF- or TNF/zVAD-induced shock while 
cytokine/chemokine levels do not necessarily correlate with survival. This is 
supported by the fact that we demonstrate evidence of liver endothelial cell but not 
hematopoietic cell necroptosis via pMLKL activation. Thus, in our model, the 
hematopoietic cells which drive proinflammatory signaling do not seem to succumb 
to necroptosis, which could reduce their numbers and dampen the inflammatory 
response. Instead, necroptosis of non-hematopoietic lineages such as liver 
endothelial cells may potentiate inflammatory signaling by releasing DAMPs and 
sustaining the hematopoietic cell-driven proinflammatory response. 
Although the factors dictating the type of cell death induced in vivo are not 
well understood, the activation status of caspase-8 and balance of anti-apoptotic 
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and pro-necroptotic proteins may dictate the decision. Expression differences in 
cIAP, cFLIP, RIPK3, and MLKL levels and the localized tissue context may 
sensitize certain cell types to apoptosis or necroptosis89. Mlkl-/- mice are partially 
sensitive to TNF-induced hypothermia, suggesting that necroptosis contributes to, 
but is not the only cause of, TNF-induced shock227. Meanwhile, intestinal epithelial 
cell-specific deletion of RIPK3 phenocopied the resistance of Ripk3-/- mice to TNF-
induced shock, arguing for RIPK3-mediated signaling or death in the intestine as 
the determining factor227. We found a slight but significant decrease in the amount 
of apoptosis induced in the ileum, but not colon, of TNF-treated Ripk1D138N/D138N 
mice compared to WT, but no TNF-induced intestinal permeability increase. While 
TNF did induce intestinal permeability increases in WT mice, we could not detect 
systemic evidence of bacteremia. These results suggest that TNF-induced 
apoptosis does not mediate increases in TNF-induced intestinal permeability97,313. 
However, RIPK1 kinase-dependent signaling or apoptosis may mediate Paneth 
and/or goblet cell dysfunction or death in the intestine, leading to decreased 
expression of anti-microbial peptides and defensins, and a reduction in mucin 
levels172,313. Bacterial translocation during TNF-induced shock could converge on 
the liver via the portal vein, with microbial products influencing endothelial cell 
dysfunction and death. Independently of their pro-death effects, RIPK1 kinase 
activity and RIPK3 have recently been shown to promote VEGF-induced vascular 
permeability via p38 and HSP27 signaling344. Thus, RIPK1- and RIPK3-dependent 
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signaling and/or pro-death effects in intestinal epithelial and vascular endothelial 
cells may mediate TNF-induced shock.  
In addition to TNF-induced effects on intestinal epithelial and vascular 
permeability and dysfunction, mice undergoing TNF-induced shock exhibit rapid 
drops in heart rate and mean arterial pressure, leading to hypotension. 
Interestingly, co-administration of zVAD with TNF sensitizes mice to these 
cardiovascular effects while inhibiting soluble guanylate cyclase with methylene 
blue prevents hemodynamic collapse and lethality298,345. Additionally, recent 
literature has shown that stabilizing the vascular barrier is protective in various 
mouse models of shock and sepsis, even when proinflammatory signaling and the 
cytokine storm are not ameliorated332,333. Thus, lethality during TNF- and 
TNF/zVAD-induced shock seems to be driven in large part by dysfunction or 
collapse of the cardiovascular system. Loss of blood pressure and edema due to 
increased vascular permeability contributes to clotting and multi-organ failure, 
ultimately resulting in death of the animal. While we observe evidence of liver 
endothelial necroptosis in WT but not RIPK1 kinase inactive TNF/zVAD-treated 
mice, RIPK1 kinase activity also leads to increases in intestinal epithelial and 
vascular endothelial permeability and clotting in response to either TNF or 
TNF/zVAD administration. While not addressed in this thesis, future studies should 
examine the role of RIPK1 kinase activity in mediating cardiac dysfunction and 
hypotension. Additionally, RIPK1 kinase activity may be required in signaling 
pathways mediating increases in epithelial and/or vascular permeability344, or in 
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up-regulating tissue factor expression on hematopoietic and/or endothelial cells, 
thus contributing to the clotting observed in TNF- and TNF/zVAD-treated WT mice. 
Some caveats and limitations of our study are that we do not know whether 
TNF- or TNF/zVAD-induced cytokines/chemokines (such as IFN-γ) converge on 
liver endothelial cells (or other cell types) to mediate dysfunction and/or cell death 
in a RIPK1 kinase-dependent manner. The kinetics of TNF/zVAD-induced shock 
are rapid and fully penetrant, whereas variations in SIRS symptoms are more 
pronounced during TNF-induced shock. It is plausible that this variability precluded 
us from detecting MLKL activation in TNF-treated mice and may reflect that less 
liver endothelial cell necroptosis is induced compared to TNF/zVAD-treated mice, 
consistent with the differences in kinetics. Additionally, even though neutrophil 
recruitment to the lung or liver is unaffected in resistant reconstituted mice, 
neutrophils can mediate damage through release of ROS and proteases. This 
could exacerbate cytokine production and inflammation, but RIPK1 kinase inactive 
cells may be resistant to these effects. Our bone marrow chimera data 
demonstrating protection from TNF- or TNF/zVAD-induced shock in 
Ripk1D138N/D138N hosts raise the issue of RIPK1 kinase inactive radiation-resistant 
tissue-resident macrophages, such as liver Kupffer cells (KC). KCs are present in 
the lumen of liver sinusoids and act as sensors of gut-derived bacteria and 
microbial products346. Upon activation they release ROS and secrete cytokines 
and chemokines. During Listeria monocytogenes infection, KCs have been shown 
to undergo necroptosis329. Thus, radiation-resistant Ripk1D138N/D138N KCs may not 
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secrete inflammatory cytokines or undergo necroptosis in response to microbial 
products or DAMPs released during shock. We will need to address this caveat by 
depleting macrophages with clodronate liposomes prior to testing the degree of 
resistance in TNF- and TNF/zVAD-treated WT  Ripk1D138N/D138N chimeras.  
Future studies will need to further elucidate the role of RIPK1 
phosphorylation in apoptotic and necroptotic signaling to better understand its 
regulation. To date, the only known target of RIPK1 kinase activity is RIPK1 itself. 
Since RIPK1 can mediate both apoptosis and necroptosis in a kinase-dependent 
manner, what other complex components are phosphorylated during pro-death 
signaling? Alternatively, if RIPK1 indeed targets only itself for auto-
phosphorylation, more clarity is needed to understand how regulation of its 
ubiquitination, phosphorylation, and conformational changes determine the 
signaling outcome171,241,242.  
While we were able to show that liver endothelial cells undergo pMLKL 
activation and necroptosis during TNF/zVAD-induced shock in vivo, genetic 
evidence suggests that both caspase-8 dependent activity and MLKL-dependent 
necroptosis contribute to TNF-induced shock227. A systematic study of caspase-8- 
and MLKL-dependent responses to TNF- and TNF/zVAD-induced shock would be 
useful to assess the contribution of apoptosis or necroptosis (or death-independent 
signaling effects) to epithelial and endothelial barrier permeability increases, 
clotting, cytokine/chemokine levels, hypothermia, and lethality. We attempted to 
assess the role of RIPK1 kinase activity in endothelial cells by utilizing tamoxifen-
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inducible VeERT2Cre Ripk1D138N/FL mice. However, the resistance of D138N 
heterozygous mice (Ripk1D138N/+) precluded us from this genetic approach (Figure 
9). Thus, the generation of conditional RIPK1 D138N and conditional MLKL mice 
will allow investigation of organ- and cell type-specific induction of apoptosis and/or 
necroptosis in TNF- and TNF/zVAD-induced shock. For instance, determining the 
contribution of RIPK1 kinase activity specifically in intestinal epithelial cells or in 
the endothelium to TNF- and TNF/zVAD-induced inflammation, permeability, 
clotting, and death. 
While our study revealed a crucial role for RIPK1 kinase activity in driving 
TNF- and TNF/zVAD-induced shock, the literature regarding the contribution of 
RIPK1, RIPK3, and MLKL to LPS-induced shock or the more relevant cecal ligation 
and puncture (CLP) sepsis model is unclear24,40,41,48,97,227,270,335. Thus, it will be 
important to examine the involvement of RIPK1 kinase activity in LPS- versus 
LPS/zVAD-induced shock and in the polymicrobial sepsis (CLP) model. 
Additionally, RIPK3 conditional, RIPK3 kinase inactive, and MLKL-deficient mice 
should be tested in these models. These future studies will be crucial to further 
elucidating the exact role of RIPK1 kinase activity and pro-necroptotic regulators 
in various cell types during models of shock and sepsis. Work in this thesis 
presents evidence for a role of RIPK1 kinase-mediated endothelial cell necroptosis 
in the liver and direct or indirect effects on intestinal and vascular permeability and 
clotting during TNF- and TNF/zVAD-induced shock. Thus, RIPK1 kinase inhibitors 
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should be tested in patients as they may have promise in ameliorating 
inflammatory vascular injury and/or SIRS.  
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